Equibles

6-K

MEDICURE INC (MCUJF)

6-K 2020-11-12 For: 2020-09-30
View Original
Added on April 06, 2026

UNITED STATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

FORM 6-K

REPORT OFFOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THESECURITIES EXCHANGE ACT OF 1934

For the month of November2020

Commission File Number: 001-31995

MEDICUREINC.

(Translation of registrant's name into English)

2-1250 Waverley Street

Winnipeg, MB Canada R3T 6C6

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 8a72____.

EXHIBITLIST

Exhibit Title
99.1 Q3 Financial Statements
99.2 Q3 Management’s Discussion and Analysis
99.3 CEO Certification
99.4 CFO Certification

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Medicure Inc.
(Registrant)
Date: November 11, 2020 By: /s/ Dr. Albert D. Friesen
Dr. Albert D. Friesen
Title: CEO

Exhibit 99.1

Condensed Consolidated Interim Financial Statements

(Expressed in thousands of Canadian Dollars, except per share amounts)

MEDICURE INC.

Three and nine months ended September 30, 2020

(unaudited)

In accordance with National Instruments 51-102 released by the Canadian Securities Administrators, the Company discloses that its auditors have not reviewed the unaudited financial statements for the three and nine months ended September 30, 2020.

Condensed Consolidated Interim Statements of Financial Position

(expressed in thousands of Canadian dollars, except per share amounts)

(unaudited)

Note September 30, 2020 December 31, 2019
****<br><br>Assets
Current assets:
Cash and cash equivalents $ 11,871 $ 12,965
Accounts receivable 3 & 9 6,206 10,216
Inventories 4 6,202 6,328
Prepaid expenses 1,233 1,855
Total current assets 25,512 31,364
Non-current assets:
Property, plant and equipment 1,058 1,282
Intangible assets 5 & 6 8,048 9,599
Other assets 27 39
Total non-current assets 9,133 10,920
Total assets $ 34,645 $ 42,284
****<br><br>Liabilities and Equity
Current liabilities:
Accounts payable and accrued liabilities 5 & 11(b) $ 5,462 $ 9,384
Current portion of royalty obligation 7 716 872
Current portion of acquisition payable 5 667 649
Income taxes payable 474 517
Current portion of lease obligation 263 240
Total current liabilities 7,582 11,662
Non-current liabilities
Royalty obligation 7 725 1,176
Acquisition payable 5 1,158 1,655
Lease obligation 684 849
Total non-current liabilities 2,567 3,680
Total liabilities 10,149 15,342
Equity:
Share capital 8(b) 84,232 85,364
Warrants 8(d) 1,949 1,949
Contributed surplus 8,267 8,028
Accumulated other comprehensive income (5,790 ) (5,751 )
Deficit (64,162 ) (62,648 )
Total Equity 24,496 26,942
Total liabilities and equity $ 34,645 $ 42,284
Commitments and contingencies 10(a) & 10(d)
Subsequent events 8(b)

See accompanying notes to the condensed consolidated interim financial statements.

| 2 |

| --- |

Condensed Consolidated Interim Statements of Net Loss and ComprehensiveLoss

(expressed in thousands of Canadian dollars, except per share amounts)

(unaudited)

Note Three months ended<br> <br>September 30, 2020 Three months<br><br> ended<br><br> September 30,<br><br>2019 Nine months ended<br> <br>September 30, 2020 Nine months<br><br> ended<br><br>September 30,<br><br>2019
Revenue, net $ 3,549 $ 5,519 $ 9,235 $16,700
Cost of goods sold 4 & 5 1,363 1,496 4,381 3,887
Gross profit 2,186 4,023 4,854 12,813
Expenses
Selling 9 923 3,349 3,963 10,796
General and administrative 9 1,264 1,044 2,834 2,748
Research and development 9 737 976 1,693 3,078
2,924 5,369 8,490 16,622
Finance (income) costs:
Finance (income) expense, net 7 99 (116 ) (208 ) (488)
Foreign exchange (gain) loss, net 210 (601 ) (936 ) 1,093
309 (717 ) (1,144 ) 605
Net loss before income taxes $ (1,047 ) $ (629 ) $ (2,492 ) $(4,414)
Income tax recovery
Current — (30 ) — (102)
Net loss $ (1,047 ) $ (599 ) $ (2,492 ) $(4,312)
Other comprehensive (loss) income:
Item that may be reclassified to profit or loss
Exchange differences on translation <br>of foreign subsidiaries (272 ) 195 (39 ) (1,293)
Item that will not be reclassified to profit or loss:
Revaluation of investment in <br>Sensible Medical at FVOCI 6 — (212 ) — (456)
Other comprehensive loss, net of tax (272 ) (17 ) (39 ) (1,749)
Comprehensive loss $ (1,319 ) $ (616 ) $ (2,531 ) $(6,061)
Loss per share
Basic 8 (e) $ (0.10 ) $ (0.04 ) $ (0.23 ) $(0.28)
Diluted 8 (e) $ (0.10 ) $ (0.04 ) $ (0.23 ) $(0.28)

See accompanying notes to the condensed consolidated interim financial statements.

| 3 |

| --- |

Condensed Consolidated Interim Statements of Changes in Equity(expressed in thousands of Canadian dollars, except per share amounts)

(unaudited)

Note Share<br> Capital Warrants Contributed<br> Surplus Accumulated <br>other <br>comprehensive income <br>(loss) Equity <br>(Deficit) Total
Balance, December 31, 2018 $ 122,887 $ 1,949 $ 7,628 $ 1,268 $ (50,138 ) $ 83,594
Net loss for the nine months ended<br>      September 30, 2019 — — — — (4,312 ) (4,312 )
Other comprehensive loss for the nine months ended September 30, 2019 — — — (1,749 ) — (1,749 )
Transactions with owners, recorded directly in equity
Buy-back of common shares under NCIB 8 (b) (5,955 ) — — — 1,812 (4,143 )
Share-based compensation 8 (c) — — 280 — — 280
Stock options exercised 8 (c) 37 — (17 ) — — 20
Total transactions with owners (5,918 ) — 263 — 1,812 (3,843 )
Balance, September 30, 2019 $ 116,969 $ 1,949 $ 7,891 $ (481 ) $ (52,638 ) $ 73,690
Note Share<br> Capital Warrants Contributed<br> Surplus Accumulated<br> <br>other<br> <br>comprehensive income<br> <br>(loss) Equity<br> <br>(Deficit) Total
Balance, December 31, 2019 $ 85,364 $ 1,949 $ 8,028 $ (5,751 ) $ (62,648 ) $ 26,942
Net loss for the nine months ended <br><br>September 30, 2020 — — — — (2,492 ) (2,492 )
Other comprehensive income for the nine months ended September 30, 2020 — — — (39 ) — (39 )
Transactionswith owners, recorded directly in equity
Buy-back of common shares<br> <br>under NCIB 8 (b) (1,132 ) — — — 978 (154 )
Share-based compensation 8 (c) — — 239 — — 239
Total transactions with owners (1,132 ) — 239 — 978 85
Balance, September 30, 2020 $ 84,232 $ 1,949 $ 8,267 $ (5,790 ) $ (64,162 ) $ 24,496

See accompanying notes to the condensed consolidated interim financial statements.

| 4 |

| --- |

Condensed Consolidated Interim Statements of Cash Flows

(expressed in thousands of Canadian dollars, except per share amounts)

(unaudited)

For the nine months ended September 30 Note 2020 2019
Cash (used in) provided by:
Operating activities:
Net loss for the period $ (2,492 ) $ (4,312 )
Adjustments for:
Current income tax recovery — (102 )
Amortization of property, plant and equipment 224 382
Amortization of intangible assets 5 1,838 667
Share-based compensation 8(c) 239 280
Write-down of inventories 4 311 578
Finance income, net (208 ) (488 )
Unrealized foreign exchange (gain) loss (476 ) 7
Change in the following:
Accounts receivable 4,022 (655 )
Inventories (185 ) (4,610 )
Prepaid expenses 622 750
Accounts payable and accrued liabilities (4,589 ) (3,350 )
Interest received, net 26 1,609
Income taxes paid (57 ) (477 )
Royalties paid 7 (326 ) (1,133 )
Cash flows used in operating activities (1,051 ) (10,854 )
Investing activities:
Investment in Sensible Medical 6 — (6,337 )
Redemption of short-term investments — 47,747
Acquisition of property, plant and equipment — (186 )
Acquisition of intangible assets 5 & 6 — (13,660 )
Cash flows from investing activities — 27,564
Financing activities:
Purchase of common shares under normal course issuer bid 8(b) (154 ) (4,145 )
Exercise of stock options 8(c) — 20
Cash flows used in financing activities (154 ) (4,125 )
Foreign exchange gain (loss) on cash held in foreign currency 111 (1,023 )
(Decrease) increase in cash and cash equivalents (1,094 ) 11,562
Cash and cash equivalents, beginning of period 12,965 24,139
Cash and cash equivalents, end of period $ 11,871 $ 35,701

See accompanying notes to the condensed consolidated interim financial statements.

| 5 |

| --- |

Notes to the Condensed Consolidated Interim Financial Statements

(expressed in thousands of Canadian dollars, except per share amounts)

(unaudited)

1. Reporting entity

Medicure Inc. (the "Company") is a company domiciled and incorporated in Canada and as of October 24, 2011, its Common Shares are listed on the TSX Venture Exchange (“TSX-V”). Prior to October 24, 2011 and beginning on March 29, 2010, the Company's Common Shares were listed on the NEX board of the TSX-V. Prior to March 29, 2010, the Company's Common Shares were listed on the Toronto Stock Exchange. Additionally, the Company's shares were listed on the American Stock Exchange (later called NYSE Amex and now called NYSE MKT) on February 17, 2004 and the shares ceased trading on the NYSE Amex effective July 3, 2008. The Company remains a U.S. Securities and Exchange Commission registrant. The address of the Company's registered office is 2-1250 Waverley Street, Winnipeg, Manitoba, Canada, R3T 6C6.

The Company is a biopharmaceutical company engaged in the research, development and commercialization of human therapeutics. Through its subsidiary, Medicure International, Inc., the Company has rights to the commercial product AGGRASTAT^®^ Injection (tirofiban hydrochloride) in the United States and its territories (Puerto Rico, U.S. Virgin Islands, and Guam). AGGRASTAT^®^, a glycoprotein GP IIb/IIIa receptor antagonist, is used for the treatment of acute coronary syndrome including unstable angina, which is characterized by chest pain when one is at rest, and non-Q-wave myocardial infarction.

On September 30, 2019 the Company acquired ownership of ZYPITAMAG^TM^ from Cadila Healthcare Ltd., India (“Zydus”) for the U.S. and Canadian markets. The Company previously had acquired U.S. marketing rights with a profit-sharing arrangement on December 14, 2017. With this acquisition the Company obtained full control of the product including marketing and pricing negotiation for ZYPITAMAG^TM^. ZYPITAMAG^TM^ is used for the treatment of patients with primary hyperlipidemia or mixed dyslipidemia and was approved in July 2017 by the U.S. Food and Drug Administration (“FDA”) for sale and marketing in the United States. On May 1, 2018 ZYPITAMAG^TM^ was made available in retail pharmacies throughout the United States.

The Company’s ongoing research and development activities include the continued development and further implementation of its regulatory, brand and life cycle management strategy for AGGRASTAT^®^ and the development of additional cardiovascular products. The Company continues to seek to acquire or license additional cardiovascular products.

2. Basis of preparation of financial statements
(a) Statement of compliance
--- ---

These condensed consolidated interim financial statements of the Company and its subsidiaries were prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and Interpretations issued by the International Financial Reporting Interpretations Committee (“IFRIC”).

These condensed consolidated interim financial statements have been prepared in accordance with International Accounting Standard (“IAS”) 34 InterimFinancial Reporting and have been prepared using the same accounting policies and methods of application as those used in the Company’s audited consolidated financial statements for the year ended December 31, 2019. These condensed consolidated interim financial statements do not include all of the information required for full annual consolidated financial statements and should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2019.

The condensed consolidated interim financial statements were authorized for issue by the Board of Directors on November 10, 2020.

The Company is closely monitoring the outbreak of the novel strain of coronavirus, specifically identified as “COVID-19”, which has resulted in governments worldwide enacting emergency measures to combat the spread of the virus. These measures, which include the implementation of travel bans, self-imposed quarantine periods and social distancing, have caused material disruption to businesses globally resulting in an economic slowdown. Global equity markets have experienced significant volatility and weakness. Governments and central banks have reacted with significant monetary and fiscal interventions designed to stabilize economic conditions. The duration and impact of the COVID-19 outbreak is unknown at this time, as is the efficacy of the government and central bank interventions. It is not possible to reliably estimate the length and severity of these developments and the impact on the liquidity, financial results and condition of the Company and its operating subsidiaries in future periods.

| 6 |

| --- |

Notes to the Condensed Consolidated Interim Financial Statements

(expressed in thousands of Canadian dollars, except per share amounts)

(unaudited)

2. Basis of preparation of financial statements (continued)
(b) Basis of presentation
--- ---

The condensed consolidated interim financial statements have been prepared on the historical cost basis except for the following items:

· Derivative financial instruments are measured at fair value.
· Financial instruments at fair value through profit or loss (“FVTPL”)<br>are measured at fair value.
--- ---
· Financial instruments at fair value through other comprehensive<br>income (“FVOCI”) are measured at fair value.
--- ---
(c) Functional and presentation currency
--- ---

The condensed consolidated interim financial statements are presented in Canadian dollars, which is the Company's functional currency. All financial information presented has been rounded to the nearest thousand dollar, except where indicated otherwise.

(d) Use of estimates and judgments

The preparation of these condensed consolidated financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, revenue and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

Areas where management has made critical judgments in the process of applying accounting policies and that have the most significant effect on the amounts recognized in the condensed consolidated interim financial statements include the determination of the Company’s and its subsidiaries’ functional currencies.

Information about key assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment to the carrying amount of assets and liabilities within the next financial year are included in the following notes to the consolidated financial statements for the year ended December 31, 2019:

· Note 3(c)(i): The valuation of the investment in Sensible Medical
· Note 3(c)(iii): The valuation of the royalty obligation
--- ---
· Note 3(e): The provisions for returns, chargebacks, rebates and discounts
--- ---
· Note 3(j): The measurement of intangible assets
--- ---
· Note 3(p): The measurement of the amount and assessment of the recoverability of income tax assets<br>and income tax provisions
--- --- 
| 7 |

| --- |

Notes to the Condensed Consolidated Interim Financial Statements

(expressed in thousands of Canadian dollars, except per share amounts)

(unaudited)

3. Accounts Receivable
September 30, 2020 December 31, 2019
--- --- --- --- ---
Trade accounts receivable $ 6,109 $ 10,136
Other accounts receivable 97 80
$ 6,206 $ 10,216

As at September 30, 2020, there were three customers with amounts owing greater than 10% of the Company’s accounts receivable which totaled 97% in aggregate (Customer A – 25%, Customer B – 44%, Customer C – 28%). As at December 31, 2019, there were three customers with amounts owing greater than 10% of the Company’s accounts receivable which totaled 96% in aggregate (Customer A – 41%, Customer B – 28%, Customer C – 27%).

4. Inventories
September 30, 2020 December 31, 2019
--- --- --- --- ---
Finished product available-for-sale $ 5,234 $ 5,273
Unfinished product and packaging materials 968 1,055
$ 6,202 $ 6,328

Inventories expensed as part of cost of goods sold during the three and nine months ended September 30, 2020 amounted to $757 and $2,220, respectively, (2019 – $678 and $2,642). During the three and nine months ended September 30, 2020, the Company wrote-off inventory totaling nil and $311, respectively, (2019 – $578 and $578) that had expired or was otherwise unusable through cost of goods sold on the statement of loss and comprehensive loss.

| 8 |

| --- |

Notes to the Condensed Consolidated Interim Financial Statements

(expressed in thousands of Canadian dollars, except per share amounts)

(unaudited)

5. Intangible assets

Cost Licenses Patents and Drug Approvals Trademarks Customer list Total
At December 31, 2018 $ 1,910 $ 15,484 $ 4,365 $ 770 $ 22,529
Additions (note 6) 7,038 8,930 — — 15,968
Impairment (6,959 ) — — — (6,959 )
Transfers within intangible assets (1,854 ) 1,457 — — (397 )
Effect of movements in exchange rates (135 ) (942 ) (209 ) (37 ) (1,323 )
At December 31, 2019 $ — $ 24,929 $ 4,156 $ 733 $ 29,818
Effect of movements in exchange rates — 673 112 20 805
At September 30, 2020 $ — $ 25,602 $ 4,268 $ 753 $ 30,623
Accumulated amortization and<br> impairment losses Licenses Patents and Drug Approvals Trademarks Customer list Total
At December 31, 2018 $ 205 $ 15,484 $ 4,365 $ 770 $ 20,824
Amortization 841 597 — — 1,438
Impairment (638 ) — — — (638 )
Transfers within intangible assets (397 ) — — — (397 )
Effect of movements in exchange rates (11 ) (751 ) (209 ) (37 ) (1,008 )
At December 31, 2019 $ — $ 15,330 $ 4,156 $ 733 $ 20,219
Amortization — 1,838 — — 1,838
Effect of movements in exchange rates — 386 112 20 518
At September 30, 2020 $ — $ 17,554 $ 4,268 $ 753 $ 22,575
Carrying amounts Licenses Patents and Drug Approvals Trademarks Customer list Total
At December 31, 2019 $ — $ 9,599 $ — $ — $ 9,599
At September 30, 2020 $ — $ 8,048 $ — $ — $ 8,048

On September 30, 2019 the Company acquired ownership of ZYPITAMAG^TM^ for the U.S. and Canadian markets. Under terms of the agreement, Zydus received an upfront payment of U.S. $5,000 (CDN $6,622) and U.S. $2,000 (CDN $2,649) in deferred payments to be paid in equal instalments annually over the next four years, as well as contingent payments on the achievement of milestones and royalties related to net sales. The Company previously had acquired U.S. marketing rights with a profit-sharing arrangement. With this acquisition the Company obtained full control of marketing and pricing negotiation for ZYPITAMAG^TM^. Upon completion of the acquisition $8,930 was recorded within patents and drug approvals relating to the upfront and deferred payments and $1,457 was transferred from licenses to patents and drug approvals pertaining to the cost of the previously acquired license over ZYPITAMAG^TM^. The fair value of the deferred payments of $667, $667 and $1,158 is recorded on the statement of financial position within accounts payable and accrued liabilities, current portion of acquisition payable and acquisition payable, respectively, as at September 30, 2020. The initial amortization period pertaining to the ZYPITAMAG^TM^ intangible assets was 4.3 years with the remaining amortization period being 3.3 years as at September 30, 2020.

| 9 |

| --- |

Notes to the Condensed Consolidated Interim Financial Statements

(expressed in thousands of Canadian dollars, except per share amounts)

(unaudited)

5. Intangible assets (continued)

The Company has considered indicators of impairment as at September 30, 2020 and December 31, 2019. The Company did not record any impairment as for the three and nine months ended September 30, 2020 or 2019. The Company recorded a write-down of intangible assets related to the ReDS^TM^license during the year ended December 31, 2019 totaling $6,321 as a result of uncertainties with ReDS^TM^ being experienced in regards to the length of the sales cycle and uptake of the product with customers, resulting in the Company’s sales being below the committed amounts required by the exclusive marketing and distribution agreement regarding ReDS^TM^. On August 20, 2020, the Company announced the termination of the marketing and distribution agreement with Sensible pertaining to the ReDS^TM^license for the marketing of the ReDS^TM^in the United States.

With respect to the intangible asset related to ZYPITAMAG^TM^, management calculated its fair value less costs to sell using a discounted cash flow model (Level 3 in the fair value hierarchy) based upon financial forecasts prepared by management using a discount rate of 13.25%, a cumulative aggregate growth rate of 300% over four years and a nominal terminal value. The Company has concluded that there was no impairment as a result of the analysis as at September 30, 2020 or as at December 31, 2019 as the recoverable amount exceeded the carrying amount by approximately $1,600 and $1,600, respectively, at the high end of the reasonable range. However, the assessment identified that a reasonably possible change in the key assumption of the sales growth rate forecast results in the recoverable amount being less than the carrying value.  A six percent (December 31, 2019 - seven percent) reduction in the sales growth forecast per year would result in the carrying value of the intangible asset exceeding the reasonable range of the recoverable amount as at September 30, 2020.

For the three and nine months ended September 30, 2020, amortization of intangible assets totaling $602 and $1,838, respectively, (2019 - $240 and $667) is recorded within cost of goods sold.

6. Investment in Sensible Medical

On January 24, 2019, the Company acquired a 9.36% equity interest (7.71% on a fully-diluted basis) in Sensible Medical Innovations Ltd. (“Sensible”), and concurrently entered into an exclusive marketing and distribution agreement with Sensible to market ReDS^TM^ in the United States. The Company acquired the investment and the rights for US$10,000 (CDN$13,351) plus US$68 (CDN$91) in directly attributable costs.

On completion of the transaction, the Company recorded the initial fair value assigned to the investment in Sensible Medical at $6,337 with the remainder attributed to the rights associated with the distribution agreement accounted for within intangible assets and ReDS^TM^ demonstration units which were recorded within property, plant and equipment. $7,038 was recorded within intangible assets relating to the license acquired through the exclusive marketing and distribution agreement and $67 was recorded within property’ plant and equipment pertaining to ReDS^TM^ demonstration devices acquired as part of the agreement.

The Company made an irrevocable election at initial recognition to recognize changes in the fair value of the investment in Sensible Medial through other comprehensive loss, as this is a strategic investment, and the Company considers this classification to be more relevant. As noted above, the initial fair value assigned to the investment upon initial recognition was $6,337. During the year ended December 31, 2019, the Company recorded other comprehensive loss of $6,337 associated with the change in fair value of the investment in Sensible Medical. This resulted in a carrying value as at December 31, 2019 of one dollar. The change in the fair value of the investment in Sensible Medical is as a result of uncertainties with ReDS^TM^ being experienced in regards to the length of the sales cycle and uptake of the product with customers resulting in lower than expected amounts being paid to Sensible Medical under the exclusive marketing and distribution agreement. The Company did not record any other comprehensive income during the three and nine months ended September 30, 2020 as a result of the investment in Sensible Medical. During the three and nine months ended September 30, 2019, the Company recorded other comprehensive loss of $212 and $456, respectively, associated with the change in fair value of the investment in Sensible Medical.

| 10 |

| --- |

Notes to the Condensed Consolidated Interim Financial Statements

(expressed in thousands of Canadian dollars, except per share amounts)

(unaudited)

6. Investment in Sensible Medical (continued)

The license was being amortized over the term of the license agreement which was equal to ten years. During the three and nine months ended September 30, 2020, no amortization was recorded as the license was previously written down to nil. During the three and nine months ended September 30, 2019, $174 and $467, respectively, of amortization was recorded within cost of goods sold pertaining to amortization of this license. The Company recorded a write-down of intangible assets related to the ReDS^TM^license during the year ended December 31, 2019 totaling $6,321 resulting in a carrying value of nil as at December 31, 2019. On August 20, 2020, the Company announced the termination of the marketing and distribution agreement with Sensible for the marketing of the ReDS^TM^in the United States. In connection with the termination, Sensible and the Company have entered into a transition agreement which provides additional compensation to the Company for sales to customer leads provided by Medicure.

The exclusive marketing and distribution agreement with Sensible included a period of co-exclusivity, whereby Sensible may sell, market, and distribute products directly to customers in select states of the United States using its own sales force. The Company is currently eligible to receive 20% of the revenue earned by Sensible from such sales during the co-exclusivity period, and may be eligible to receive up to 35% of the revenue earned by Sensible upon certain conditions being met. During the three and nine months ended September 30, 2020, the Company recorded revenue of nil and $89, respectively, (2019 - $117 and $272) relating to sales made by Sensible.

7. Royalty obligation

On July 18, 2011, the Company settled its then existing long-term debt with Birmingham Associates Ltd. ("Birmingham"), an affiliate of Elliott Associates L.P., in exchange for i) $4,750 in cash; ii) 2,176,003 common shares of the Company; and iii) a royalty on future AGGRASTAT^®^ sales until May 1, 2023. The royalty is based on 4% of the first $2,000 of quarterly AGGRASTAT^®^ sales, 6% on the portion of quarterly sales between $2,000 and $4,000 and 8% on the portion of quarterly sales exceeding $4,000, payable within 60 days of the end of the preceding three-month periods ended February 28, May 31, August 31 and November 30. Birmingham has a one-time option to switch the royalty payment from AGGRASTAT^®^ to a royalty on the sale of MC-1. Management determined there is no value to the option to switch the royalty to MC-1 as the product is not commercially available for sale and the extended long-term development timelines associated with commercialization of the product.

In accordance with the terms of the agreement, if the Company were to dispose of its AGGRASTAT^®^ rights, the acquirer would be required to assume the obligations under the royalty agreement.

The royalty obligation was recorded at its fair value at the date at which the liability was incurred, estimated to be $902, and subsequently measured at amortized cost using the effective interest rate method at each reporting date. This resulted in a carrying value as at September 30, 2020 of $1,441 (December 31, 2019 – $2,048) of which $716 (December 31, 2019 – $872) represents the current portion of the royalty obligation. The net change in the royalty obligation for the three and nine months ended September 30, 2020 of $41 and a recovery of $344 (2019 – $98 and $297) is recorded within finance (income) expense, net on the condensed consolidated interim statements of net (loss) income and comprehensive loss. Royalties for the three and nine months ended September 30, 2020 totaled $126 and $338, respectively, (2019 – $267 and $840) with payments made during the three and nine months ended September 30, 2020 of $nil and $326, respectively (2019 – $293 and $1,133).

8. Capital Stock

(a) Authorized

The Company has authorized share capital of an unlimited number of common voting shares, an unlimited number of Class A common shares and an unlimited number of preferred shares. The preferred shares may be issued in one or more series, and the directors may fix prior to each series issued, the designation, rights, privileges, restrictions and conditions attached to each series of preferred shares.

| 11 |

| --- |

Notes to the Condensed Consolidated Interim Financial Statements

(expressed in thousands of Canadian dollars, except per share amounts)

(unaudited)

8. Capital Stock (continued)

(b) Shares issued and outstanding (continued)

Shares issued and outstanding are as follows:

Number of Common Shares Amount
Balance, December 31, 2018 15,547,812 $ 122,887
Shares issued upon exercise of stock options 8,001 37
Shares purchased and cancelled under a normal course issuer bid^(1)^ (751,800 ) (5,955 )
Shares purchased and cancelled under a substantial issuer bid^(2)^ (4,000,000 ) (31,605 )
Balance, shares outstanding December 31, 2019 10,804,013 $ 85,364
Shares purchased and cancelled under a normal course issuer bid^(1)^ (141,700 ) (1,132 )
Balance, shares outstanding September 30, 2020 10,662,313 $ 84,232
^(1)^ On May 16, 2018, the Company<br>announced that the TSX-V accepted the Company's notice of its intention to make a normal course issuer bid (the "2018 NCIB").<br>Under the terms of the 2018 NCIB, the Company could have acquired up to an aggregate of 794,088 common shares, representing five<br>percent of the common shares outstanding at the time of the application, over the twelve-month period that the 2018 NCIB was in<br>place. The 2018 NCIB commenced on May 28, 2018 and ended on May 27, 2019.
--- ---

On May 30, 2019, the Company announced that the TSX-V accepted the Company's notice of intention to make an additional normal course issuer bid (the "2019 NCIB"). Under the terms of the 2019 NCIB, the Company could have acquired up to an aggregate of 761,141 common shares, representing five percent of the common shares outstanding at the time of the application, over the twelve-month period that the 2019 NCIB was in place. The 2019 NCIB commenced on May 30, 2019 and ended on May 29, 2020.

During the year ended December 31, 2019, the Company repurchased and cancelled 751,800 common shares as a result of the 2018 NCIB and 2019 NCIB. The aggregate price paid for these common shares totaled $4,145. During the year ended December 31, 2019 the Company recorded $1,810 directly in its deficit representing the difference between the aggregate price paid for these common shares and a reduction of the Company’s share capital totaling $5,955.

During the three and nine months ended September 30, 2020, the Company repurchased and cancelled nil and 141,700 common shares, respectively, as a result of the 2019 NCIB. The aggregate price paid for these common shares totaled $154. During the three and nine months ended September 30, 2020, the Company recorded nil and $978, respectively, directly in its deficit representing the difference between the aggregate price paid for these common shares and a reduction of the Company’s share capital totaling nil and $1,132, respectively.

On June 29, 2020, the Company announced that the TSX-V accepted the Company's notice of its intention to make a normal course issuer bid (the "2020 NCIB"). Under the terms of the 2020 NCIB, the Company may acquire up to an aggregate of 533,116 common shares, representing five percent of the common shares outstanding at the time of the application, over the twelve-month period that the 2020 NCIB was in place. The 2020 NCIB commenced on June 30, 2020 and will end on June 29, 2021, or on such earlier date as the Company may complete its maximum purchases allowed under the 2020 NCIB.

| 12 |

| --- |

Notes to the Condensed Consolidated Interim Financial Statements

(expressed in thousands of Canadian dollars, except per share amounts)

(unaudited)

8. Capital Stock (continued)

(b) Shares issued and outstanding (continued)
^(2)^ On December 20, 2019, the<br>Company completed a Substantial Issuer Bid (“SIB”) pursuant to which the Company purchased 4,000,000 of its common<br>shares for cancellation at a set purchase price of $6.50 per common share for a total purchase price of $26,000 in cash. The Company<br>incurred an additional $139 of transaction costs related to the SIB for a total aggregate purchase price paid of $26,139. During<br>the year ended December 31, 2019, the Company recorded $5,466 directly in its deficit representing the difference between the aggregate<br>price paid for these common shares and a reduction of the Company’s share capital totaling $31,605.
--- ---

Subsequent to September 30, 2020 the Company purchased 211,000 common shares for cancellation for a total cost of $205.

(c) Stock option plan

The Company has a stock option plan which is administered by the Board of Directors of the Company with stock options granted to directors, management, employees and consultants as a form of compensation. The number of common shares reserved for issuance of stock options is limited to a maximum of 2,934,403 common shares of the Company at any time. The stock options generally have a maximum term of between five and ten years and vest within a five-year period from the date of grant.

Changes in the number of options outstanding during the nine months ended September 30, 2020 and 2019 is as follows:

Nine months ended September 30 2020 2019
Options Weighted<br> average<br> exercise<br> price Options Weighted<br> average<br> exercise<br> price
Balance, beginning of period 1,428,408 $ 3.67 1,394,642 $ 3.91
Granted — — 262,000 4.95
Exercised — — (8,001 ) (2.45 )
Forfeited, cancelled or expired (63,450 ) (5.50 ) (191,083 ) (6.97 )
Balance, end of period 1,364,958 $ 3.59 1,457,558 $ 3.70
Options exercisable, end of period 1,101,358 $ 2.99 1,038,708 $ 2.74

Options outstanding at September 30, 2020 consist of the following:

Range of<br> exercise prices Weighted<br> average <br>remaining<br> contractual life Options outstanding<br> weighted average<br> exercise price Number<br> exercisable
$ 0.30 185,000 2.60 years $ 0.30 185,000
$ 0.31 - 3.00 536,933 1.54 years $ 1.59 536,933
$ 3.01 - 4.00 29,000 0.15 years $ 3.90 29,000
$ 4.01 - 5.00 222,800 3.74 years $ 4.95 92,000
$ 5.01 - 7.30 391,225 2.02 years $ 7.09 258,425
$ 0.30 - 7.30 1,364,958 2.15 years $ 3.59 1,101,358

All values are in US Dollars.

| 13 |

| --- |

Notes to the Condensed Consolidated Interim Financial Statements

(expressed in thousands of Canadian dollars, except per share amounts)

(unaudited)

8. Capital Stock (continued)

(c) Stock option plan (continued)

Compensation expense related to stock options granted during the period or from previous periods under the stock option plan for the three and nine months ended September 30, 2020 is $65 and $239, respectively, (2019 – $108 and $280). The compensation expense was determined based on the fair value of the options at the date of measurement using the Black-Scholes option pricing model. The expected life of stock options is based on historical data and current expectations and is not necessarily indicative of exercise patterns that may occur. The expected volatility reflects the assumption that the historical volatility over a period similar to the life of the options is indicative of future trends, which may not necessarily be the actual outcome.

(d) Warrants

On November 17, 2016 in connection with a term loan entered into to fund an acquisition, the Company issued 900,000 warrants to the lenders, exercisable for a 48-month period following the issuance of the loan at a price of $6.50 per share. The fair value of the warrants issued in connection with the loan was $2,066 net of its pro-rata share of financing costs of $117 and were recorded in equity with a corresponding balance recorded as deferred financing costs which were netted against the associated long-term debt which has since been repaid in full.

Changes in the number of Canadian dollar denominated warrants outstanding during the nine months ended September 30, 2020 and 2019 are as follows:

Nine months ended September 30 2020 2019
Options Weighted<br> average<br> exercise<br> price Options Weighted<br> average<br> exercise<br> price
Balance, beginning of period 900,000 $ 6.50 900,000 $ 6.50
Balance, end of period 900,000 $ 6.50 900,000 $ 6.50
Warrants exercisable, end of period 900,000 $ 6.50 900,000 $ 6.50
(e) Per share amounts
--- ---

The following table reflects the share data used in the denominator of the basic and diluted loss per share computations for the three and nine months ended September 30, 2020 and 2019:

Three months ended<br> <br>September 30, 2020 Three months<br><br> ended <br>September 30, 2019 Nine months<br> <br>ended<br> <br>September 30, 2020 Nine months <br>ended <br>September 30,<br><br> 2019
Weighted average shares outstanding for <br> basic loss per share 10,662,313 14,888,656 10,739,369 15,239,918
Effects of dilution from:
Stock options — — — —
Warrants — — — —
Weighted average shares outstanding for <br> diluted loss per share 10,662,313 14,888,656 10,739,369 15,239,918 
| 14 |

| --- |

Notes to the Condensed Consolidated Interim Financial Statements

(expressed in thousands of Canadian dollars, except per share amounts)

(unaudited)

8. Capital Stock (continued)

(e) Per share amounts (continued)

Effects of dilution from 1,364,958 stock options and 900,000 warrants were excluded in the calculation of weighted average shares outstanding for diluted income per share for the three and nine months ended September 30, 2020 as they are anti-dilutive. Effects of dilution from 1,457,558 stock options and 900,000 warrants were excluded in the calculation of weighted average shares outstanding for diluted loss per share for the three and nine months ended September 30, 2019 as they are anti-dilutive.

9. Government assistance

During the three and nine months ended September 30, 2020, the Company recorded $404 and $729, respectively, (2019 – nil and nil) in government assistance resulting from the Canada Emergency Wage Subsidy. The funding has been recorded as a reduction of the related salary expenditures with $311 and $559, respectively, recorded within selling expenses, $52 and $95, respectively, recorded within general and administrative expenses and $41 and $75, respectively, recorded with research and development expenses for the three and nine months ended September 30, 2020. As at September 30, 2020, $61 of government assistance is recorded in accounts receivable (December 31, 2019 - nil).

10. Commitments and contingencies

(a) Commitments

As at September 30, 2020, and in the normal course of business, the Company has obligations to make future payments representing contracts and other commitments that are known and committed as follows:

2020 - remaining $ 1,333
2021 1,311
2022 1,311
2023 200
2024 200
$ 4,355

The Company has entered into a manufacturing and supply agreement to purchase a minimum quantity of AGGRASTAT^®^unfinished product inventory totaling $200 (US$150) annually (based on current pricing) until 2024 and a minimum quantity of AGGRASTAT^®^finished product inventory totaling $341 (€218) annually (based on current pricing) until 2022 and $821 (€525) annually (based on current pricing) until 2022.

Effective January 1, 2020, the Company renewed its business and administration services agreement with GVI, as described in note 11(b), under which the Company is committed to pay $7 per month or $85 per year for a one-year term.

Contracts with contract research organizations are payable over the terms of the associated agreements and clinical trials and timing of payments is largely dependent on various milestones being met, such as the number of patients recruited, number of monitoring visits conducted, the completion of certain data management activities, trial completion, and other trial related activities.

On October 31, 2017, the Company acquired an exclusive license to sell and market PREXXARTAN^®^ (valsartan) oral solution in the United States and its territories with a seven-year term, with extensions to the term available, which had been granted tentative approval by the FDA, and which was converted to final approval during 2017. The Company acquired the exclusive license rights for an upfront payment of US$100, with an additional US$400 payable on final FDA approval and will be obligated to pay royalties and milestone payments from the net revenues of PREXXARTAN^®^. The US$400 payment is on hold pending resolution of the dispute between the licensor and the third-party manufacturer of PREXXARTAN^®^described in note 10(d) and is recorded within accounts payable and accrued liabilities on the condensed consolidated interim statements of financial position.

| 15 |

| --- |

Notes to the Condensed Consolidated Interim Financial Statements

(expressed in thousands of Canadian dollars, except per share amounts)

(unaudited)

10. Commitments and contingencies (continued)

(a) Commitments (continued)

On December 14, 2017 the Company acquired an exclusive license to sell and market ZYPITAMAG^TM^ in the United States and its territories for a term of seven years with extensions to the term available. The Company had entered into a profit-sharing arrangement resulting in a portion of the net profits from ZYPITAMAG^TM^ being paid to the licensor. No amounts are due and/or payable pertaining to profit sharing on this product and the profit-sharing arrangement was eliminated with the Company’s acquisition of ZYPITAMAG^TM^ on September 30, 2019 as described in note 5.

(b) Guarantees

The Company periodically enters into research agreements with third parties that include indemnification provisions customary in the industry. These guarantees generally require the Company to compensate the other party for certain damages and costs incurred as a result of claims arising from research and development activities undertaken on behalf of the Company. In some cases, the maximum potential amount of future payments that could be required under these indemnification provisions could be unlimited. These indemnification provisions generally survive termination of the underlying agreement. The nature of the indemnification obligations prevents the Company from making a reasonable estimate of the maximum potential amount it could be required to pay. Historically, the Company has not made any indemnification payments under such agreements and no amount has been accrued in the condensed consolidated interim financial statements with respect to these indemnification obligations.

(c) Royalties

As a part of the Birmingham debt settlement described in note 7, beginning on July 18, 2011, the Company is obligated to pay a royalty to Birmingham based on future commercial AGGRASTAT^®^ sales until May 1, 2023. The royalty is based on 4% of the first $2,000 of quarterly AGGRASTAT^®^ sales, 6% on the portion of quarterly sales between $2,000 and $4,000 and 8% on the portion of quarterly sales exceeding $4,000 payable within 60 days of the end of the preceding three-month periods ended February 28, May 31, August 31 and November 30. Birmingham has a one-time option to switch the royalty payment from AGGRASTAT^®^ to a royalty on the sale of MC-1. Management has determined there is no value to the option to switch the royalty to MC-1 as the product is not commercially available for sale and the extended long-term development timeline associated with commercialization of the product. Royalties for the three and nine months ended September 30, 2020 totaled $126 and $338, respectively, (2019 – $267 and $840) with payments made during the three and nine months ended September 30, 2020 of $nil and $326, respectively (2019 – $293 and $1,133).

Beginning with the acquisition of ZYPITAMAG^TM^ (note 5), completed on September 30, 2019, the Company is obligated to pay royalties to Zydus subsequent to the acquisition date on net sales of ZYPITAMAG^TM^. During the three and nine months ended September 30, 2020, the Company recorded $3 and $11, respectively, in royalties in regards to ZYPITAMAG^TM^ which is recorded within cost of goods sold on the condensed consolidated interim statement of net (loss) income and comprehensive income. As at September 30, 2020, $6 (December 31, 2019 - $3) was recorded within accounts payable and accrued liabilities on the condensed consolidated interim statement of financial position in regards to these royalties.

The Company is obligated to pay royalties on any future net sales of PREXXARTAN^®^ to the licensor of PREXXARTAN^®^. To date, no royalties are due and/or payable.

(d) Contingencies

In the normal course of business, the Company may from time to time be subject to various claims or possible claims. Although management currently believes there are no claims or possible claims that if resolved would either individually or collectively result in a material adverse impact on the Company’s financial position, results of operations, or cash flows, these matters are inherently uncertain and management’s view of these matters may change in the future.

During 2018, the Company was named in a civil claim in Florida from the third-party manufacturer of PREXXARTAN^®^against the licensor. The claim disputed the rights granted by the licensor to the Company with respect to PREXXARTAN^®^. The claim against the Company has since been withdrawn, however the dispute between the licensor and the third-party manufacturer continues.

| 16 |

| --- |

Notes to the Condensed Consolidated Interim Financial Statements

(expressed in thousands of Canadian dollars, except per share amounts)

(unaudited)

10. Commitments and contingencies (continued)

(d) Contingencies (continued)

On September 10, 2015, the Company submitted a supplemental New Drug Application (“sNDA”) to the FDA to expand the label for AGGRASTAT^®^. The label change is being reviewed and evaluated based substantially on data from published studies. If the label change submission were to be successful, the Company will be obligated to pay €300 over the course of a three-year period in equal quarterly instalments following approval. On July 7, 2016, the Company received a Complete Response Letter stating the sNDA cannot be approved in its present form and requested additional information. The payments are contingent upon the success of the filing and as such the Company has not recorded any amount in the condensed consolidated interim statements of net (loss) income and comprehensive loss pertaining to this contingent liability.

During 2015, the Company began a development project of a cardiovascular generic drug in collaboration with Apicore. The Company has entered into a supply and development agreement under which the Company holds all commercial rights to the drug. In connection with this project, the Company is obligated to pay Apicore 50% of net profit from the sale of this drug. On August 13, 2018, the Company announced that the FDA has approved its ANDA for SNP, a generic intravenous cardiovascular product and the product became available commercially during the third quarter of 2019. To date, no amounts are due and/or payable pertaining to profit sharing on this product.

11. Related party transactions

(a) Key management personnel compensation

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company. The Board of Directors, President and Chief Executive Officer and Chief Financial Officer are key management personnel for all periods. Beginning on July 1, 2019, the Company appointed a new President and Chief Operating Officer who was considered key management personnel for the three and nine months ended September 30, 2020. The then existing President retained the title of Chief Executive Officer and remains included in key management personnel for all periods. The Vice-President, Commercial Operations was considered key management personnel in 2019 up to the cessation of his employment on June 30, 2019.

In addition to their salaries, the Company also provides non-cash benefits and participation in the stock option plan. The following table details the compensation paid to key management personnel:

Three months<br> <br>ended<br> <br>September 30, 2020 Three months <br>ended <br>September 30, 2019 Nine months<br> <br>ended<br> <br>September 30, 2020 Nine months <br>ended <br>September 30, 2019
Salaries, fees and short-term benefits $ 184 $ 176 $ 539 $ 569
Share-based payments 48 38 173 86
$ 232 $ 214 $ 712 $ 655
(b) Transactions with related parties

Directors and key management personnel control 24% of the voting shares of the Company as at September 30, 2020 (December 31, 2019 – 23%).

During the three and nine months ended September 30, 2020 the Company paid GVI, a company controlled by the Chief Executive Officer, a total of $21 and $64, respectively, (2019 – $21 and $64) for business administration services, $59 and $178, respectively, (2019 – $77 and $230) in rental costs and $9 and $28, respectively, (2019 – $12 and $36) for information technology support services. As described in note 10(a), the business administration services summarized above are provided to the Company through a consulting agreement with GVI.

| 17 |

| --- |

Notes to the Condensed Consolidated Interim Financial Statements

(expressed in thousands of Canadian dollars, except per share amounts)

(unaudited)

11. Related party transactions (continued)

(b) Transactions with related parties (continued)

Clinical research services are provided through a consulting agreement with GVI Clinical Development Solutions Inc. ("GVI CDS"), a company controlled by the Chief Executive Officer. Pharmacovigilance and safety, regulatory support, quality control and clinical support are provided to the Company through the GVI CDS agreement. During the three and nine months ended September 30, 2020, the Company paid GVI CDS $27 and $120, respectively, (2019 – $79 and $331) for clinical research services.

Research and development services are provided through a consulting agreement with CanAm Bioresearch Inc. ("CanAm"), a company controlled by a close family member of the Chief Executive Officer. During the three and nine months ended September 30, 2020, the Company paid $6 and $6, respectively, (2019 – nil and $118) for research and development services.

These transactions have been measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties.

As at September 30, 2020, included in accounts payable and accrued liabilities is $18 (December 31, 2019 – $95) payable to GVI, $13 (December 31, 2019 – $56) payable to GVI CDS and $7 (December 31, 2019 – nil) payable to CanAm. These amounts are unsecured, payable on demand and non-interest bearing.

Effective July 18, 2016, the Company renewed its consulting agreement with its Chief Executive Officer, through A.D. Friesen Enterprises Ltd., a company owned by the Chief Executive Officer, for a term of five years, at a rate of $300 annually, increasing to $315 annually, effective January 1, 2017 and increasing to $331 annually, effective January 1, 2019. The Company may terminate this agreement at any time upon 120 days’ written notice. There were no amounts payable to A.D. Friesen Enterprises Ltd. as a result of this consulting agreement as at September 30, 2020 or December 31, 2019. Any amounts payable to A.D. Friesen Enterprises Ltd. are unsecured, payable on demand and non-interest bearing.

12. Segmented information

Revenue generated from external customers from the marketing and distribution of commercial products for the three and nine months ended September 30, 2020, and 2019 was 100% from sales to customers in the United States.

During the nine months ended September 30, 2020, 100% of total revenue was generated from eight customers. Customer A accounted for 36%, Customer B accounted for 26% and Customer C accounted for 34% and the remaining four customers accounted for approximately 4% of revenue.

During the nine months ended September 30, 2019, 100% of total revenue was generated from eight customers. Customer A accounted for 36%, Customer B accounted for 29%, Customer C accounted for 28% and Customer D accounted for 5% and the remaining four customers accounted for 1% of revenue.

Property, plant and equipment and intangible assets are located in the following countries:

September 30, 2020 December 31, 2019
Canada $ 1,058 $ 1,282
Barbados 8,048 9,599
$ 9,106 $ 10,881
18
---

Exhibit 99.2

Management's Discussion and Analysis

for the three and nine months ended September 30, 2020

MEDICURE INC.

Prepared by Management without review by the Company’s auditor

Message to Shareholders, November 2020

AGGRASTAT^®^ (tirofiban hydrochloride) continues to have the majority of the patient market share gained over the past several years, however net revenues and margins have declined due to pricing pressures and some decreases in demand including the reduction of procedures being performed as a result of COVID 19. We continue to market AGGRASTAT^®^ and have refocused efforts in this area to support brand loyalty. With restrictions in travel and physical access to hospitals and physicians as a result of COVID 19, we have refocused our sales and marketing efforts on creative solutions for our customers and potential customers while working remotely. We expect this refocus of our efforts to benefit Medicure going forward. The trend in AGGRASTAT^®^ revenues has increased the importance of diversifying the Company’s revenue base through adding additional revenue generating products to our current product portfolio. Diversification has been provided by ZYPITAMAG^TM^ (pitavastatin magnesium) tablets. Management is also focused on efficient marketing innovations to contain costs and return to profitability.

Medicure continues to focus on the sales and marketing of AGGRASTAT^®^ and ZYPITAMAG^TM^. We are pleased to have acquired ZYPITAMAG^TM^at the end of the third quarter of 2019 allowing Medicure to have full control over the product, including pricing decisions, control we did not have under our previous profit-sharing arrangement.

Medicure began selling Sodium Nitroprusside Injection 50mg/2ml (25mg/ml) single dose vial (“Sodium Nitroprusside” or “SNP”) in January of 2020 and we have additional Abbreviated New Drug Applications (“ANDAs”) being developed for other cardiovascular products in our pipeline as well as a cardiovascular biosimilar product.

In December of 2019, Medicure completed a substantial issuer bid (“SIB”) and purchased and subsequently cancelled 4.0 million of our common shares at a set purchase price of $6.50 per common share for a total purchase price of $26.0 million in cash. This SIB was funded from the Company’s existing cash on hand and provided a good return to our valued shareholders on the successful divestment of Apicore.

We are in unprecedented times in the world with the current COVID 19 pandemic and the safety of our employees, customers and other stakeholders is at the forefront of importance. At the same time, Medicure remains focused on the business and growing revenue and earnings. On behalf of the Board of Directors, I want to thank our shareholders, stakeholders and employees for their continued support while we manage our business. We remain committed to creating value for you and look forward to what lies ahead for Medicure.

Yours sincerely,

Albert D. Friesen, Ph.D.

Chairman and Chief Executive Officer

| 2 |

| --- |

Management’sDiscussion and Analysis

The following management’s discussion and analysis (“MD&A”) is current as of November 10, 2020 and should be read in conjunction with Medicure Inc.’s (“Medicure” or the “Company”) audited consolidated financial statements for year ended December 31, 2019 which have been prepared under International Financial Reporting Standards (“IFRS”), the Company's annual report on Form 20-F for the year ended December 31, 2019 and the unaudited condensed consolidated interim financial statements for the three and nine months ended September 30, 2020. This MD&A was prepared with reference to National Instrument 51-102 “Continuous Disclosure Obligations” of the Canadian Securities Administrators. Except as otherwise noted, the financial information contained in this MD&A and in the Company’s consolidated financial statements has been prepared in accordance with IFRS. Additional information regarding the Company is available on SEDAR at www.sedar.com and at the Company's website at www.medicure.com.

All dollar amounts here within are expressed in thousands of Canadian dollars, except per share amounts and where otherwise noted.

FORWARD-LOOKING STATEMENTS

This MD&A contains forward-looking information as defined in applicable securities laws (referred to herein as “forward-looking statements”) that reflect the Company’s current expectations and projections about its future results. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on the current assumptions, estimates, analysis and opinions of management of the Company made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors which the Company believes to be relevant and reasonable in the circumstances.

The Company uses words such as “believes,” “may,” “plan,” “will,” “estimate,” “continue,” “anticipates,” “intends,” “expects,” and similar expressions to identify forward-looking statements, which, by their very nature, are not guarantees of the Company’s future operational or financial performance, and are subject to risks and uncertainties, both known and unknown, as well as other factors that could cause the Company’s actual results, performance, prospects or opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

Specifically, this MD&A contains forward-looking statements regarding, but not limited to:

· The Company’s expectations in regards to the extent and impact of COVID 19 including the<br>timing surrounding these impacts;
· the Company’s intention to sell and market its acute care cardiovascular drug, AGGRASTAT^®^,<br>in the United States and its territories through its U.S. subsidiary, Medicure Pharma Inc.;
--- ---
· the Company’s intention to sell and market its cardiovascular drug, ZYPITAMAG^TM^,<br>in the United States and its territories through its U.S. subsidiary, Medicure Pharma Inc.;
--- ---
· the Company’s intention to sell and market its cardiovascular drug, SNP, in the United States<br>and its territories through its U.S. subsidiary, Medicure Pharma Inc.;
--- ---
· the Company’s intention to develop and implement clinical, regulatory and other plans to<br>generate an increase in the value of AGGRASTAT^®^;
--- ---
· the Company’s intention to expand or otherwise improve the approved indications and/or dosing<br>information contained within AGGRASTAT^®^’s approved prescribing information;
--- ---
· the Company’s intention to increase sales of AGGRASTAT^®^;
--- ---
· the Company’s intention to increase sales of ZYPITAMAG^TM^;
--- ---
· the Company’s intention to increase sales of the Company’s generic version of SNP;
--- ---
· the Company’s intention to launch PREXXARTAN^®^(valsartan) oral solution (“PREXXARTAN^®”^^”^),<br>which is currently on hold pending resolution of the dispute between Carmel Biosciences Inc. (“Carmel”) and<br>the third-party manufacturer of PREXXARTAN^®^;
--- ---
· the Company’s intention to develop a cardiovascular biosimilar product in connection with<br>an agreement with Reliance Life Sciences Private Limited (“RLS”);
--- --- 
| 3 |

| --- |

Management’sDiscussion and Analysis

· the Company’s intention to develop pyridoxal 5 phosphate (“P5P”) or TARDOXAL^TM^,<br>formerly MC-1, for neurological disorders or other applications;
· the Company’s intention to investigate and advance certain other product opportunities;
--- ---
· the Company’s intention to develop and commercialize additional cardiovascular generic drug<br>products;
--- ---
· the Company’s intention and ability to obtain regulatory approval for its products and potential<br>products;
--- ---
· the Company’s expectations with respect to the cost of the testing and commercialization<br>of its products and potential products;
--- ---
· the Company’s sales and marketing strategy;
--- ---
· the Company’s anticipated sources of revenue;
--- ---
· the Company’s intentions regarding the protection of its intellectual property;
--- ---
· the Company’s intention to identify, negotiate and complete business development transactions<br>(e.g. the sale, purchase, or license of pharmaceutical products or services);
--- ---
· the Company’s business strategy; and
--- ---
· the Company’s expectation that it will not pay dividends in the foreseeable future.
--- ---

Inherent in forward-looking statements are known and unknown risks, uncertainties and other factors beyond the Company’s ability to predict or control that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risk factors include, among others, the Company’s future product revenues, stage of development, additional capital requirements, risks associated with the completion and timing of clinical trials and obtaining regulatory approval to market the Company’s products, the ability to protect its intellectual property, dependence upon collaborative partners, changes in government regulation or regulatory approval processes, and rapid technological change in the industry. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements.

Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this MD&A. Such statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions about:

· general business and economic conditions;
· the extent and impact of the COVID 19 outbreak on our business including any impact on our customers,<br>contract manufacturers and other third-party service providers;
--- ---
· the impact of changes in Canadian-U.S. dollar and other foreign exchange rates on the Company's<br>revenues, costs and results;
--- ---
· the timing of the receipt of regulatory and governmental approvals for the Company's research and<br>development projects;
--- ---
· the availability of financing for the Company's commercial operations and/or research and development<br>projects, or the availability of financing on reasonable terms;
--- ---
· results of current and future clinical trials;
--- ---
· the uncertainties associated with the acceptance and demand for new products;
--- ---
· clinical trials not being unreasonably delayed and expenses not increasing substantially;
--- ---
· government regulation not imposing requirements that significantly increase expenses or that delay<br>or impede the Company's ability to bring new products to market;
--- ---
· the Company's ability to attract and retain skilled management and staff;
--- --- 
| 4 |

| --- |

Management’sDiscussion and Analysis

· the Company’s ability, amid circumstances and decisions that are out of the Company’s<br>control, to maintain adequate supply of product for commercial sale;
· inaccuracies and deficiencies in the scientific understanding of the interaction and effects of<br>pharmaceutical treatments when administered to humans;
--- ---
· market competition;
--- ---
· tax benefits and tax rates; and
--- ---
· the Company's ongoing relations with its employees and with its business partners.
--- ---

Although management of the Company believes that these forward-looking statements are based on reasonable assumptions, a number of factors could cause the actual results, performance or achievements of the Company to be materially different from the future results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking statements contained in this MD&A, and any documents incorporated by reference herein, are expressly qualified by this cautionary statement. The Company cautions the reader that the foregoing list of important factors and assumptions is not exhaustive. Events or circumstances could cause actual results to differ materially from those estimated or projected and expressed in, or implied by, these forward-looking statements. The reader should also carefully consider the matters discussed under “Risk Factors” in this MD&A which provides for additional risks and uncertainties relating to the Company and its business. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of factors, whether as a result of new information or future events or otherwise, other than as may be required by applicable legislation.

OVERVIEW OF THE COMPANY

Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the United States cardiovascular market. The Company’s present focus is the sale and marketing of its cardiovascular products, AGGRASTAT^®^, ZYPITAMAG^TM^ and SNP. The products are distributed in the United States and its territories through the Company’s U.S. subsidiary, Medicure Pharma Inc. The Company’s registered office and head office is located at 2-1250 Waverley Street, Winnipeg, Manitoba, R3T 6C6.

The Company’s first commercial product was AGGRASTAT^®^, a glycoprotein inhibitor (“GPI”), used for the treatment of acute coronary syndrome (“ACS”), including unstable angina (chest pain) (“UA”), which is characterized by chest pain when one is at rest, and non Q wave myocardial infarction (“MI”). The Company acquired an exclusive license to sell ZYPITAMAG^TM^ in the U.S. and launched ZYPITAMAG^TM^ in May 2018 in the United States and in September 2019 acquired full rights and ownership of ZYPITAMAG^TM^. The Company received approval in August of 2018 from the FDA for its first ANDA for SNP and Medicure’s product became available during the third quarter of 2019 in the United States with initial sales beginning during 2020.

The Company’s research and development program is focused on making selective research and development investments in certain additional acute cardiovascular generic and reformulation product opportunities, as well as continuing the development and implementation of its regulatory, brand and life cycle management strategy for AGGRASTAT^®^. The Company is also continuing to explore neurological treatment applications of its legacy product P5P (MC-1, TARDOXAL^TM^). On August 20, 2020, the Company announced that it entered into a License, Manufacture and Supply Agreement with RLS for a cardiovascular biosimilar product. The Company is focused on the development of additional cardiovascular generic drugs which is expected to transform the Company’s commercial suite of products to four or more approved products in 2021.

Through the sale of AGGRASTAT^®^ and ZYPITAMAG^TM^ experienced over recent years as well as the staged acquisition and subsequent sale of the Apicore business completed in 2016 and 2017 the Company’s financial position has improved significantly compared to previous years. The Company completed a SIB in December of 2019 where it purchased and cancelled 4.0 million common shares at a set purchase price of $6.50 per common share resulting in the payment of $26,000. After the closing of the transaction and despite lower cash balances and working capital levels, the Company’s financial position remains strong.

The ongoing focus of the Company includes the sale of AGGRASTAT^®^, ZYPITAMAG^TM^ and SNP and the development of additional cardiovascular products. In parallel with the Company’s ongoing commitment to support AGGRASTAT^®^, its valued customers and the continuing efforts of the commercial organization, the Company is in the process of developing and further implementing its regulatory, brand and life cycle management strategy for AGGRASTAT^®^. The objective of this effort is to further expand AGGRASTAT^®^’s share of the GPI inhibitor market in the United States. GPIs are injectable platelet inhibitors used in the treatment of patients with ACS. The marketing and sales of ZYPITAMAG^TM^ became a key focus of the Company during 2018 and throughout 2019 and 2020 and the marketing and sales of ReDS^TM^ was a key focus of the Company from the first quarter of 2019 and through the first half of 2020, with SNP sales beginning during early 2020.

| 5 |

| --- |

Management’sDiscussion and Analysis

The Company has historically financed its operations principally through the net revenue received from the sale of AGGRASTAT^®^, ZYPITAMAG^TM^, ReDS^TM^and SNP, the sale of its equity securities, the issuance and subsequent exercises of warrants and stock options, interest on excess funds held and the issuance of debt. As announced on October 3, 2017, the Company sold the Apicore business for net proceeds to Medicure of approximately US$105,000, as well as additional contingent payments. The funds generated from the sale of Apicore were partially used to repay the Company’s long-term debt, fund the SIB completed in 2019 and the remaining funds will continue to be used to finance the Company’s operations, development and growth moving forward.

On January 28, 2019, the Company entered into an agreement with Sensible Medical Innovations Inc. ("Sensible") to become the exclusive marketing partner for ReDS™ in the United States. ReDS™ is a non-invasive, U.S Food and Drug Administration (“FDA”) cleared medical device that provides an accurate, actionable and absolute measurement of lung fluid which is important in the management of congestive heart failure. ReDS™ was already being marketed to United States hospitals by Sensible and the Company began marketing ReDS™ immediately using its existing commercial organization*.* Under the terms of the agreement, Medicure was to receive a percentage of total U.S. sales revenue from the device and was to have met minimum annual sales quotas.  In addition, Medicure invested US$10,000 in Sensible for a 7.71% equity stake on a fully diluted basis and in connection with this investment the Company acquired the license for ReDS™ in the United States. On August 20, 2020, the Company announced the termination of the marketing of the ReDS^TM^device in the United States. In connection with the termination, Sensible and the Company have entered into a transition agreement which provides additional compensation to the Company for sales to customer leads provided by Medicure. The Company continues to hold its equity stake, and will continue to support Sensible in its transition to a new marketing and distribution arrangement in order to secure its investment in Sensible Medical.

RECENT DEVELOPMENTS

COVID-19

The Company is monitoring the outbreak of the novel strain of coronavirus, specifically identified as COVID-19, which has resulted in governments worldwide enacting emergency measures to combat the spread of the virus. These measures, which include the implementation of travel bans, self-imposed quarantine periods and social distancing, have caused material disruption to businesses globally resulting in an economic slowdown. Global equity markets have experienced significant volatility and weakness. Governments and central banks have reacted with significant monetary and fiscal interventions designed to stabilize economic conditions. The duration and impact of the COVID-19 outbreak is unknown at this time, as is the efficacy of the government and central bank interventions. It is not possible to reliably estimate the length and severity of these developments and the impact on the liquidity, financial results and condition of the Company and its operating subsidiaries in future periods.

AGREEMENT WITH RLS FOR THE MARKETING RIGHTS OF A CARDIOVASCULARBIOSIMILAR

On October 5, 2020, the Company announced that it has entered into a License, Manufacture and Supply Agreement with RLS for a cardiovascular biosimilar product. The Company is responsible for the regulatory approval process for the product. A biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an approved reference product. The Agreement grants an exclusive right to the Company to market and sell the product in the United States of America, Canada and the European Union.

TREATMENT OF THROMBOTIC COMPLICATIONS DUE TO COVID-19

On August 24, 2020, the Company reported that early investigator sponsored clinical reports evaluating the efficacy of AGGRASTAT^®^ showed promise for preventing and treating thrombotic complications due to COVID-19. AGGRASTAT^®^ is not currently indicated for use in patients with COVID-19.

Notably, a non-randomized, case-controlled, investigator sponsored proof of concept study (n=10) evaluating AGGRASTAT^®^ in combination with standard of care in patients with severe COVID-19 and hypercoagulability found that enhanced platelet inhibition improves hypoxemia (https://clinicaltrials.gov/ct2/show/NCT04368377). Treated patients experienced a mean reduction in alveolar-arterial oxygen gradient and an increase in PaO2/FiO2 (ratio of partial arterial pressure of oxygen to fraction of inspired oxygen) at 24h, 48h and 7 days after treatment. Seven other small clinical reports have recently been published exploring the clinical efficacy of AGGRASTAT^®^ in patients with COVID-19.

The Company is evaluating sponsorship of further US-based randomized clinical studies to rapidly assess the efficacy and safety of using AGGRASTAT^®^ for preventing thrombotic complications due to COVID-19.

| 6 |

| --- |

Management’sDiscussion and Analysis

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain COVID-19 (or SARS-2 Coronavirus) at this time. A list of the reports referred to can be provided upon request.

TERMINATION OF REDS^TM^ MARKETINGAND DISTRIBUTION AGREEMENT

On August 20, 2020, the Company announced the termination of the marketing and distribution agreement with Sensible for the marketing of the ReDS^TM^Pro (“ReDSPro”) device in the United States. In connection with the termination, Sensible and the Company have entered into a transition agreement which provides additional compensation to the Company for sales to customer leads provided by the Company.

The Company continues to hold a 7.71% equity stake, on a fully diluted basis, in Sensible. The Company will continue to support Sensible in its transition to a new marketing and distribution arrangement in order to secure its investment in Sensible Medical. The termination of the marketing and distribution agreement with Sensible followed an in-depth strategic review of its alignment with the Company’s other lines of business

NORMAL COURSE ISSUER BID

On June 29, 2020, the Company announced that the TSX Venture Exchange ("TSXV") has accepted the Company's notice of intention to make a normal course issuer bid ("NCIB").

Under the terms of the NCIB, Medicure may acquire up to an aggregate of 533,116 common shares. In the opinion of the Company, its common shares have been trading at prices that do not reflect its underlying value. Accordingly, the Company believes that purchasing its common shares for cancellation, at present pricing, represents an opportunity to enhance value for its shareholders.

As of June 29, 2020, the Company had 10,662,313 common shares outstanding, of which 4,655,353 common shares represent the public float of the Company. Under TSXV policies, the Company is entitled to purchase up to the maximum of 533,116 common shares, representing 5% of the common shares outstanding, over the 12-month period that the NCIB is in place.

The NCIB will commence on June 30, 2020 and will end on June 29, 2021, or on such earlier date as the Company may complete its maximum purchases under the NCIB. The actual number of common shares which will be purchased, if any, and the timing of such purchases will be determined by the Company. All common shares purchased by the Company will be purchased on the open market through the facilities of TSXV by PI Financial Corp. ("PI") acting on behalf of the Company in accordance with the policies of the TSXV and will be surrendered by the Company to its transfer agent for cancellation. The prices that the Company will pay for common shares purchased will be the market price of the shares at the time of purchase.

The Company also announces that it has entered into an automatic share purchase plan with PI (the “Plan”) in order to facilitate repurchases of its common shares under the NCIB. Under the Plan, PI may purchase common shares at times when the Company would ordinarily not be permitted to do so, due to regulatory restrictions or self-imposed blackout periods.

Purchases under the Plan will be made by PI based upon parameters prescribed by the TSXV, applicable Canadian securities laws and terms of the Plan.

Subsequent to September 30, 2020, the Company purchase 211,000 common shares for cancellation for a total cost of $205 to the Company.

On December 20, 2019, the Company completed a Substantial Issuer Bid pursuant to which the Company purchased 4,000,000 of its common shares for cancellation at a set purchase price of $6.50 per common share for a total purchase price of $26.0 million in cash.

Under the Company’s previous NCIB, which expired on May 29, 2020, the Company purchased and cancelled 563,000 of its common shares between May 30, 2019 and May 29, 2020 for a total cost to the Company of $2.2 million.

POSITIVE RESULTSFOR AGGRASTAT^®^ IN THE FABOLUS-FASTER TRIAL AND PUBLICATON

On June 29, 2020, the Company announced that results from the investigator sponsored FABOLUS-FASTER Phase 4 clinical trial, using AGGRASTAT^®^, have been published in Circulation, a peer-reviewed journal of the American Heart Association.

| 7 |

| --- |

Management’sDiscussion and Analysis

FABOLUS-FASTER studied different regimens of intravenous platelet inhibitors, notably AGGRASTAT^®^ (tirofiban hydrochloride) injection (an IV GP IIb/IIIa inhibitor) and cangrelor (an IV P2Y12 inhibitor) in the early phase of primary PCI.

The FABOLUS-FASTER study randomized 122 P2Y12-naive STEMI patients to receive tirofiban (n=40), cangrelor (n=40), or a 60 mg loading dose of prasugrel (n=42). Those randomized to prasugrel were sub-randomized to chewed (n=21) or integral (n=21) tablet administration. The study was powered to test the noninferiority of cangrelor compared with tirofiban, the superiority of both tirofiban and cangrelor compared with chewed prasugrel, and superiority of chewed prasugrel compared with integral prasugrel for the primary endpoint of 30-minute inhibition of platelet aggregation (IPA) after stimulation with (20 µmol/L) ADP.

The results from the FABOLUS-FASTER trial showed cangrelor did not reach non-inferiority with tirofiban; in fact, tirofiban achieved superior IPA over cangrelor at 30 minutes (95.0%±9.0% vs 34.1%±22.5%; P <0.001). Cangrelor and tirofiban were both superior to chewed prasugrel (10.5%±11.0%, P<0.001 for both comparisons), which did not provide higher IPA over integral prasugrel (6.3%±11.4%; P=0.47).^1^

Results from FABOLUS-FASTER were recently presented virtually at the PCR e-Course Scientific Sessions, due to the cancellation of EuroPCR 2020. Complete results from this study were published on June 27, 2020 in Circulation, a peer-reviewed journal of the American Heart Association.

DIRECT TO PATIENT ONLINE PHARMACY PROGRAMOF DISTRIBUTION OF ZYPITAMAG^TM^

On June 25, 2020, the Company announced the launch of a direct to patient online pharmacy program for the distribution of ZYPITAMAG^TM^in the United States.

This program offers many advantages to the Company to facilitate an increase in patient access to ZYPITAMAG^TM^ for patients who hold a prescription, which includes direct shipment of the product to a patient’s home at no cost, the processing of prior authorizations, and direct to patient refill reminders. Ultimately, marketing and distribution of ZYPITAMAG^TM^through this program will provide reduced costs to the patient, including no retail pharmacy filling fees, and increase the availability of the product to consumers. It also provides a seamless process for physicians and prescribers, and reduces their workload by processing any prior authorization.

COMMERCIAL

In fiscal 2007, the Company through its wholly owned Barbadian subsidiary, Medicure International Inc., acquired the U.S. rights to its first commercial product, AGGRASTAT^®^, in the United States and its territories (Puerto Rico, Virgin Islands, and Guam). AGGRASTAT^®^, a GPI, is used for the treatment of ACS, including UA, which is characterized by chest pain when one is at rest, and non Q wave MI. AGGRASTAT^®^ is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non ST elevation acute coronary syndrome (“NSTE ACS”). Under a contract with Medicure International Inc., the Company’s wholly owned U.S. subsidiary, Medicure Pharma Inc., continues to support, market and distribute the product.

Net AGGRASTAT^®^ product sales for three and nine months ended September 30, 2020 were $3,439 and $8,722, respectively, compared to $5,324 and $16,341, respectively, during the three and nine months ended September 30, 2019.

The Company primarily sells finished AGGRASTAT^®^ to drug wholesalers. These wholesalers subsequently sell AGGRASTAT^®^to hospitals where health care providers administer the drug to patients. Wholesaler management decisions to increase or decrease their inventory of AGGRASTAT^®^may result in sales of AGGRASTAT^®^to wholesalers that do not track directly with demand for the product at hospitals. The Company has set up a portal called Medicure Direct to market the Company’s branded and generic products directly to hospitals and pharmacies with initial sales expected to occur in the fourth quarter of 2020 through this initiative.

Hospital demand for AGGRASTAT^®^ has been lower during the first nine months of 2020 when compared to the prior year, however the number of hospital customers using AGGRASTAT^®^ continued to remain strong leading to patient market share held by the product of approximately 65% as of September 30, 2020. The Company's commercial team continues to work on expanding its customer base, however this continued increase in the customer base for AGGRASTAT^®^ has not directly resulted in corresponding revenue increases as the Company continues to face increased competition resulting from further genericizing of the Integrilin market which has created pricing pressures on AGGRASTAT^®^ combined with lower hospital demand for the product including a reduction in procedures being performed as a result of COVID 19. The Company continues to expect strong patient market share despite reduced revenue from the AGGRASTAT^®^ brand and diversifying revenues away from a single product became increasingly important to the Company.

| 8 |

| --- |

Management’sDiscussion and Analysis

The number of new customers that reviewed and implemented AGGRASTAT^®^ increased sharply safter October 11, 2013 as a result of FDA approval of the High Dose Bolus (“HDB”) regimen for AGGRASTAT^®^ and due to increased marketing and promotional efforts of the Company.

All of the Company’s sales are denominated in U.S. dollars and the U.S. dollar improved in value against the Canadian dollar during the three and nine months ended September 30, 2020 when compared to the three and nine months ended September 30, 2019. This led to increased AGGRASTAT^®^revenues, however this was offset by the increasing price pressures facing AGGRASTAT^®^ when comparing the two periods as well as decreases in demand.

On December 5, 2019, the Company announced it had filed a patent infringement action against Nexus Pharmaceuticals, Inc. (“Nexus”) in the U.S. District Court for the Northern District of Illinois, alleging infringement of the ‘660 patent.

The patent infringement action is in response to Nexus’ filing of an ANDA seeking approval from the FDA to market a generic version of AGGRASTAT^®^ before the expiration of the ’660 patent.

The ‘660 patent is listed in the FDA’s orange book with an expiry date of May 1, 2023. Medicure will vigorously defend the ’660 patent and will pursue the patent infringement action against Nexus and all other legal options available to protect its product.

Previously, on November 16, 2018, the Company filed a patent infringement action against Gland Pharma Ltd. (“Gland”) in the U.S. District Court for the District of New Jersey, alleging infringement of the ‘660 patent. The patent infringement actions were in response to Gland’s filing of an ANDA seeking approval from the FDA to market a generic version of AGGRASTAT^®^ before the expiration of the ’660 patent.

On August 21, 2019 the Company announced that its subsidiary, Medicure International Inc., has settled this ongoing patent infringement action. As part of the settlement, Gland has acknowledged that the ‘660 patent is valid, enforceable and infringed. The settlement resulted in the Company entering into a license agreement with Gland with an anticipated launch date for Gland’s generic product of March 1, 2023. The remaining terms of the settlement are confidential.

On September 30, 2019 the Company announced that it had acquired the ownership of ZYPITAMAG^TM^ from Zydus for U.S. and Canadian markets. Under terms of the agreement, Zydus will receive an upfront payment of US$5,000 and US$2,000 in deferred payments to be made over the next four years, as well as contingent payments on achievement of milestones and royalties related to net sales. With this acquisition Medicure obtained full control of marketing and pricing negotiations for the product.

Previously, on December 14, 2017, the Company acquired from Zydus, an exclusive license to sell and market ZYPITAMAG^TM^, a branded cardiovascular drug, in the United States and its territories for a term of seven years with extensions to the term available. ZYPITAMAG^TM^ is used for the treatment of patients with primary hyperlipidemia or mixed dyslipidemia and was approved in July 2017 by the FDA for sale and marketing in the United States. On May 1, 2018 ZYPITAMAG^TM^ became commercially available in retail pharmacies throughout the United States. The Company’s product launch utilized its existing commercial infrastructure and while not an in-hospital product like AGGRASTAT^®^, ZYPITAMAG^TM^ added to the Company’s cardiovascular portfolio and expanded the Company’s reach to new patients. ZYPITAMAG^TM^ contributed revenue of $105 and $371, respectively, to the Company for the three and nine months ended September, 2020 compared to $78 and $87 during the three and nine months ended September 30, 2019. The Company continues to work towards growing the ZYPITAMAG^TM^ brand, usage of the product and revenues from ZYPITAMAG^TM^.

On June 25, 2020, the Company announced the launch of a direct to patient online pharmacy program for the distribution of ZYPITAMAG^TM^in the United States.

This program offers many advantages to the Company to facilitate an increase in patient access to ZYPITAMAG^TM^ for patients who hold a prescription, which includes direct shipment of the product to a patient’s home at no cost, the processing of prior authorizations, and direct to patient refill reminders. Ultimately, marketing and distribution of ZYPITAMAG^TM^through this program will provide reduced costs to the patient, including no retail pharmacy filling fees, and increase the availability of the product to consumers. It also provides a seamless process for physicians and prescribers, and reduces their workload by processing any prior authorization.

On October 3, 2019, the Company announced that it has reached a preferred pricing agreement with the ADAP Crisis Task Force for ZYPITAMAG^TM^. The agreement will open access to ZYPITAMAG^TM^ tablets to low income, underinsured and uninsured Americans who qualify for ADAP coverage in states where ZYPITAMAG^TM^ has been adopted onto the ADAP formulary.

| 9 |

| --- |

Management’sDiscussion and Analysis

The ADAP Crisis Task Force negotiates reduced drug prices for all ADAP formularies. ADAP formularies provide HIV treatment to low income, uninsured, and underinsured individuals living with HIV/AIDS in all 50 states and the US territories. The ADAP Crisis Task Force was formed in 2002, and is currently comprised of representatives from Arizona, California, Florida, Illinois, Massachusetts, New York, North Carolina, Tennessee, Texas, Virginia, and Washington state HIV/AIDS divisions.

On August 13, 2018, the Company announced that the FDA has approved its ANDA for SNP. SNP is indicated for the immediate reduction of blood pressure for adult and pediatric patients in hypertensive crisis. The product is indicated for producing controlled hypotension in order to reduce bleeding during surgery and for the treatment of acute congestive heart failure. The filing of the ANDA was previously announced by the Company on December 13, 2016. Medicure’s SNP has recently become available in the United States with sales of $5 and $53, respectively, being recorded for the three and nine months ended September 30, 2020 from SNP.

On October 31, 2017, the Company acquired an exclusive license to sell and market PREXXARTAN^®^, which treats hypertension, in the U.S. and its territories from Carmel for a seven-year term with extensions to the term available. Medicure acquired the license rights for an upfront payment of US$100, with an additional US$400 payable on final FDA approval. Carmel would also be entitled to receive royalties and milestone payments from the net revenues of PREXXARTAN^®^. PREXXARTAN^®^ had been granted tentative approval by the FDA and the tentative approval was converted to final approval on December 19, 2017.

As announced on March 19, 2018 and updated on March 28, 2018, all PREXXARTAN^®^related activities were placed on hold by the Company pending the resolution of a dispute that Medicure became aware of between the owner of the New Drug Application (“NDA”), Carmel and the third-party manufacturer of the product. The Company was also named in a civil claim in Florida between the third-party manufacturer and Carmel. The claim disputed the rights granted to Medicure by Carmel in regards to PREXXARTAN^®^. More recently the claim against the Company was withdrawn, however the dispute between Carmel and the third-party manufacturer continues.

Medicure had intended to launch PREXXARTAN^®^ during the first half of 2018. To date, only an up-front payment of US$100, has been made to Carmel in regards to PREXXARTAN^®^and the Company has reserved all of its rights under the license agreement with Carmel for PREXXARTAN^®^.

Going forward and contingent on sufficient finances being available, the Company intends to further expand revenue through marketing and promotional activities, strategic investments related to AGGRASTAT^®^ and ZYPITAMAG^TM^ and SNP, as well as the licensing, acquisition and/or development of other cardiovascular products that fit the commercial organization.

The Company is primarily focusing on:

Maintaining and growing AGGRASTAT^®^ sales in the United States

The Company continues to work to expand the sales of AGGRASTAT^®^ in the United States. The use of AGGRASTAT^®^ is recommended by the AHA and ACC Guidelines for the treatment of ACS. AGGRASTAT^®^ has been shown, to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with NSTE ACS.

As stated previously, one of the Company’s primary ongoing research and development activities is the continued development and further implementation of a new regulatory, brand and life cycle management strategy for AGGRASTAT^®^.

An important aspect of the AGGRASTAT^®^ strategy was the revision of its approved prescribing information. On October 11, 2013, the Company announced that the FDA approved the AGGRASTAT^®^ HDB regimen, as requested under Medicure's supplemental new drug application (“sNDA”). The AGGRASTAT^®^ HDB regimen (25 mcg/kg within 5 minutes, followed by 0.15 mcg/kg/min) has become the recommended dosing for the reduction of thrombotic cardiovascular events in patients with NSTE ACS.

The Company believes that further expanded indications and dosing regimens could provide added value to further maximize the revenue potential for AGGRASTAT^®^. The Company is currently exploring the potential to make such changes, and the Company may need to conduct appropriate clinical trials, obtain positive results from those trials, or otherwise provide support in order to obtain regulatory approval for such proposed indications and dosing regimens.

| 10 |

| --- |

Management’sDiscussion and Analysis

On September 1, 2016, the Company announced that it had received approval from the FDA for its bolus vial product format for AGGRASTAT^®^. The product format is a concentrated, pre-mixed, 15 ml vial designed specifically for convenient delivery of the AGGRASTAT^®^ bolus dose (25 mcg/kg). Development of the bolus vial was in response to feedback from interventional cardiologists and catheterization lab nurses from across the United States. Commercial launch of the bolus vial took place in October of 2016 and the Company continues to believe this product format will have a positive impact on hospital utilization of AGGRASTAT^®^.

The Company is also providing funding for a number of investigator sponsored research projects targeting contemporary utilization of AGGRASTAT^®^ relative to its competitors. On June 29, 2020, the Company announced that results from the investigator sponsored FABOLUS-FASTER Phase 4 clinical trial, using AGGRASTAT^®^, have been published in Circulation, a peer-reviewed journal of the American Heart Association.

Growing sales of ZYPITAMAG^TM^in the United States

On September 30, 2019 the Company announced that through its subsidiary, Medicure International Inc., it has acquired the ownership of ZYPITAMAG^TM^ from Zydus for U.S. and Canadian markets. Under terms of the agreement, Zydus will receive an upfront payment of US$5,000 and US$2,000 in deferred payments to be made over the next four years, as well as contingent payments on achievement of milestones and royalties related to net sales.

Previously, on December 14, 2017, the Company acquired from Zydus, an exclusive license to sell and market ZYPITAMAG^TM^, a branded cardiovascular drug, in the United States and its territories for a term of seven years with extensions to the term available. ZYPITAMAG^TM^ is used for the treatment of patients with primary hyperlipidemia or mixed dyslipidemia and was approved in July 2017 by the FDA for sale and marketing in the United States. On May 1, 2018 ZYPITAMAG^TM^ became commercially available in retail pharmacies throughout the United States. The Company’s product launch utilized its existing commercial infrastructure and while not an in-hospital product like AGGRASTAT^®^, ZYPITAMAG^TM^ added to the Company’s cardiovascular portfolio and expanded the Company’s reach to new patients. ZYPITAMAG^TM^ contributed revenue of $105 and $371, respectively, to the Company for the three and nine months ended September, 2020 compared to $78 and $87 during the three and nine months ended September 30, 2019. The Company continues to work towards growing the ZYPITAMAG^TM^ brand, usage of the product and revenues from ZYPITAMAG^TM^.

On June 25, 2020, the Company announced the launch of a direct to patient online pharmacy program for the distribution of ZYPITAMAG^TM^in the United States.

This program offers many advantages to Medicure to facilitate an increase in patient access to ZYPITAMAG^TM^ for patients who hold a prescription, which includes direct shipment of the product to a patient’s home at no cost, the processing of prior authorizations, and direct to patient refill reminders. Ultimately, marketing and distribution of ZYPITAMAG^TM^through this program will provide reduced costs to the patient, including no retail pharmacy filling fees, and increase the availability of the product to consumers. It also provides a seamless process for physicians and prescribers, and reduces their workload by processing any prior authorization.

Acquisitions, licensing ormarketing partnerships for new commercial products

The Company continues to explore additional opportunities for the acquisition or licensing of other cardiovascular products that fit the commercial organization.

Developing additionalcardiovascular generic and reformulation products

On August 13, 2018, the Company announced that the FDA has approved its ANDA for SNP. SNP is indicated for the immediate reduction of blood pressure for adult and pediatric patients in hypertensive crisis. The product is also indicated for producing controlled hypotension in order to reduce bleeding during surgery and for the treatment of acute congestive heart failure) The filing of the ANDA had been previously announced by the Company on December 13, 2016. Medicure’s SNP has recently become available in the United States with sales of $6 and $54, respectively, being recorded for the three and nine months ended September 30, 2020 from SNP.

Medicure is also developing two additional generic versions of acute cardiovascular drugs and is exploring other potential opportunities.

On August 20, 2020, the Company announced that it entered into a License, Manufacture and Supply Agreement with RLS for a cardiovascular biosimilar product.

| 11 |

| --- |

Management’sDiscussion and Analysis

RESEARCH AND DEVELOPMENT

The Company’s research and development activities are predominantly conducted by its wholly-owned Barbadian subsidiary, Medicure International Inc.

AGGRASTAT^®^

One of the primary ongoing research and development activities is the continued development and further implementation of a new regulatory, brand and life cycle management strategy for AGGRASTAT^®^. The extent to which the Company is able to invest in this plan is dependent upon the availability of sufficient finances and the expected returns from those investments.

An important aspect of the AGGRASTAT^®^ strategy was the revision of its approved prescribing information. On October 11, 2013, the Company announced that the FDA approved the AGGRASTAT^®^ HDB regimen, as requested under Medicure's sNDA. The AGGRASTAT^®^ HDB regimen (25 mcg/kg within 5 minutes, followed by 0.15 mcg/kg/min) has become the recommended dosing for the reduction of thrombotic cardiovascular events in patients with NSTE ACS.

The Company believes that further expanded indications and dosing regimens could provide added value to further maximize the revenue potential for AGGRASTAT^®^. The Company is currently exploring the potential to make such changes, and the Company may need to conduct appropriate clinical trials, obtain positive results from those trials, or otherwise provide support in order to obtain regulatory approval for such proposed indications and dosing regimens.

On April 23, 2015, the Company announced that the FDA approved a revision to the duration of the bolus delivery for the AGGRASTAT^®^ HDB regimen. The dosing change and label modification was requested by the Company to help health care professionals more efficiently meet patient-specific administration needs and to optimize the implementation of AGGRASTAT^®^ at new hospitals. The newly approved labeling supplement now allows the delivery duration of the AGGRASTAT^®^ HDB (25 mcg/kg) to occur anytime within 5 minutes, instead of the previously specified duration of 3 minutes. This change was part of the Company’s ongoing regulatory strategy to expand the applications for AGGRASTAT^®^.

On September 10, 2015, the Company announced that it submitted a sNDA to the FDA to expand the label for AGGRASTAT^®^ to include the treatment of patients presenting with STEMI. If approved for STEMI, AGGRASTAT^®^ would be the first in its class of GPIs to receive such a label in the United States.

In previous communication with the Company, the FDA’s Division of Cardiovascular and Renal Drug Products indicated its willingness to review and evaluate this label change request based substantially on data from the On-TIME 2 study, with additional support from published studies and other data pertinent to the use of the AGGRASTAT^®^ HDB regimen in the treatment of STEMI. The efficacy and safety of the HDB regimen in STEMI has been evaluated in more than 20 clinical studies involving over 11,000 patients and is currently recommended by the ACCF/AHA Guideline for the Management of STEMI.

On July 7, 2016, the Company received a Complete Response Letter (“CRL”) from the FDA for its sNDA requesting an expanded indication for patients presenting with STEMI. The FDA issued the CRL to communicate that its initial review of the application was completed; however, it could not approve the application in its present form and requested additional information. The Company continues to work directly with the FDA to address these comments and explore other options available.

The sNDA filing was accompanied by a mandatory US$1,200 user fee paid by Medicure International Inc. to the FDA. In December 2016, the Company received a waiver and full refund of the user fee which had been paid and expensed during fiscal 2015.

On September 1, 2016, the Company announced that it had received approval from the FDA for its bolus vial product format for AGGRASTAT^®^.

This product format is a concentrated, 15 ml vial containing sufficient drug to administer the FDA approved, HDB of 25 mcg/kg given at the beginning of treatment. AGGRASTAT^®^ is also sold in two other sizes, a 100 ml vial and a 250 ml bag. The existing, pre-mixed products continue to be available, providing a convenient concentration for administering the post-HDB maintenance infusion of 0.15 mcg/kg/min. (Approved Dosing: Administer intravenously 25 mcg/kg within 5 minutes and then 0.15 mcg/kg/min for up to 18 hours). Commercial launch of the bolus vial occurred during the fourth quarter of 2016 and the Company continues to believe this product format will have a positive impact on hospital utilization of AGGRASTAT^®^.

| 12 |

| --- |

Management’sDiscussion and Analysis

Another aspect of the AGGRASTAT^®^ strategy is to advance studies related to the contemporary use and future regulatory positioning of the product. On May 10, 2012, the Company announced the commencement of enrolment in a clinical trial of AGGRASTAT^®^ entitled SAVI-PCI. SAVI-PCI is a randomized, open-label study enrolling patients undergoing PCI at sites across the United States. The study was designed to evaluate whether patients receiving the HDB regimen of AGGRASTAT^®^ (25 mcg/kg bolus over 3 minutes) followed by an infusion of 0.15 mcg/kg/min for a shortened duration of 1 to 2 hours will have outcomes that are similar, or “non-inferior,” to patients receiving a 12 to 18-hour infusion of Integrilin® (eptifibatide) (Merck & Co., Inc.) at its FDA approved dosing regimen.

The primary objective of SAVI-PCI is to demonstrate AGGRASTAT^®^ is non-inferior to Integrilin with respect to the composite endpoint of death, PCI-related myocardial infarction, urgent target vessel revascularization, or major bleeding within 48 hours following PCI or hospital discharge. The secondary objectives of this study include the assessment of safety as measured by the incidence of major bleeding.

The first patient was enrolled in June 2012. Enrolment was completed during the fourth quarter of 2018 and on December 17, 2019, the Company announced the completion of the Shortened AGGRASTAT^®^ (tirofiban hydrochloride) injection versus Integrilin^®^ (eptifibatide) in Percutaneous Coronary Intervention (SAVI-PCI) Clinical Trial. Topline results of the SAVI-PCI trial will be communicated during the first quarter of 2021.

The Company is also providing funding for a number of investigator sponsored research projects targeting contemporary utilization of AGGRASTAT^®^ relative to its competitors. On December 12, 2019, the Company announced the completion of the FABOLUS-FASTER Phase 4 trial, a randomized, open-label, multi-center trial assessing different regimens of intravenous platelet inhibitors, notably tirofiban and cangrelor (an IV P2Y12 inhibitor) in the early phase of primary PCI.

FABOLUS-FASTER was funded by a grant from the Company. This study does not imply comparable efficacy, safety, or product interchangeability. Please note that the use of AGGRASTAT^®^ in STEMI patients has not been approved by the FDA. As of this time, neither AGGRASTAT^®^ nor any of the GP IIb/IIIa inhibitors are indicated for the use in STEMI patients. AGGRASTAT^®^ is approved for use in NSTE-ACS patients.

On June 29, 2020, the Company announced that results from the investigator sponsored FABOLUS-FASTER Phase 4 clinical trial, using AGGRASTAT^®^, have been published in Circulation, a peer-reviewed journal of the American Heart Association.

FABOLUS-FASTER studied different regimens of intravenous platelet inhibitors, notably AGGRASTAT^®^ (tirofiban hydrochloride) injection (an IV GP IIb/IIIa inhibitor) and cangrelor (an IV P2Y12 inhibitor) in the early phase of primary PCI. The FABOLUS-FASTER study randomized 122 P2Y12-naive STEMI patients to receive tirofiban (n=40), cangrelor (n=40), or a 60 mg loading dose of prasugrel (n=42). Those randomized to prasugrel were sub-randomized to chewed (n=21) or integral (n=21) tablet administration. The study was powered to test the noninferiority of cangrelor compared with tirofiban, the superiority of both tirofiban and cangrelor compared with chewed prasugrel, and superiority of chewed prasugrel compared with integral prasugrel for the primary endpoint of 30-minute inhibition of platelet aggregation (IPA) after stimulation with (20 µmol/L) ADP.

The results from the FABOLUS-FASTER trial showed cangrelor did not reach non-inferiority with tirofiban; in fact, tirofiban achieved superior IPA over cangrelor at 30 minutes (95.0%±9.0% vs 34.1%±22.5%; P <0.001). Cangrelor and tirofiban were both superior to chewed prasugrel (10.5%±11.0%, P<0.001 for both comparisons), which did not provide higher IPA over integral prasugrel (6.3%±11.4%; P=0.47).^1^

Results from FABOLUS-FASTER were recently presented virtually at the PCR e-Course Scientific Sessions, due to the cancellation of EuroPCR 2020. Complete results from this study were published on June 27, 2020 in Circulation, a peer-reviewed journal of the American Heart Association.

On August 24, 2020, the Company reported that early investigator sponsored clinical reports evaluating the efficacy of AGGRASTAT^®^ showed promise for preventing and treating thrombotic complications due to COVID-19. AGGRASTAT^®^ is not currently indicated for use in patients with COVID-19.

Notably, a non-randomized, case-controlled, investigator sponsored proof of concept study (n=10) evaluating AGGRASTAT^®^ in combination with standard of care in patients with severe COVID-19 and hypercoagulability found that enhanced platelet inhibition improves hypoxemia (https://clinicaltrials.gov/ct2/show/NCT04368377). Treated patients experienced a mean reduction in alveolar-arterial oxygen gradient and an increase in PaO2/FiO2 (ratio of partial arterial pressure of oxygen to fraction of inspired oxygen) at 24h, 48h and 7 days after treatment. Seven other small clinical reports have recently been published exploring the clinical efficacy of AGGRASTAT^®^ in patients with COVID-19.

| 13 |

| --- |

Management’sDiscussion and Analysis

The Company is evaluating sponsorship of further US-based randomized clinical studies to rapidly assess the efficacy and safety of using AGGRASTAT^®^ for preventing thrombotic complications due to COVID-19.

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain COVID-19 (or SARS-2 Coronavirus) at this time. A list of the reports referred to can be provided upon request.

Cardiovascular Generic andReformulation Products

Through an ongoing research and development investment, the Company is exploring new product opportunities in the interest of developing future sources of revenue and growth.

On August 13, 2018, the Company announced that the FDA has approved its ANDA for SNP. SNP is indicated for the immediate reduction of blood pressure for adult and pediatric patients in hypertensive crisis. The product is also indicated for producing controlled hypotension in order to reduce bleeding during surgery and for the treatment of acute congestive heart failure. The filing of the ANDA was previously announced by the Company on December 13, 2016. Medicure’s SNP has recently become available in the United States with sales of $6 and $54, respectively, being recorded for the three and nine months ended September 30, 2020 from SNP.

The Company is focused on the development of two additional cardiovascular generic drugs and expects to grow its commercial suite of products to at least four approved products in 2021.

On October 5, 2020, Medicure Inc. the Company announced that it has entered into a License, Manufacture and Supply Agreement RLS for a cardiovascular biosimilar product. Medicure is responsible for the regulatory approval process for the product. A biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an approved reference product. The Agreement grants an exclusive right to the Company to market and sell the product in the United States of America, Canada and the European Union.

The Company had been devoting resources to its research and development programs, including, but not limited to the development of TARDOXAL^TM^(pyridoxal 5 phosphate (“P5P”) formerly known as MC-1) for neurological conditions such as Tardive Dyskinesia. This work included, but was not limited to, working with the FDA to better understand and refine the next steps in development of the product. The advancement of TARDOXAL^TM^ is currently on hold. The Company changed its focus from TARDOXAL^TM^to other uses of P5P and continues to devote time and resources to the advancement of P5P development.

The following table summarizes the Company’s research and development programs, their therapeutic focus and their stage of development.

Product Candidate Therapeutic focus Stage of Development
AGGRASTAT^®^ Acute Cardiology Approved/Marketed – Additional studies underway
ZYPITAMAG^TM^ Primary Hyperlipidemia or Mixed Dyslipidemia Approved/Marketed
SNP Acute Cardiology ANDA approved/Marketed
PREXXARTAN^®^ Hypertension Approved – Commercial launch on hold
Cardiovascular Biosimilar Acute Cardiology Development underway
Generic ANDA 2 Acute Cardiology ANDA filed
Generic ANDA 3 Acute Cardiology Formulation development underway
TARDOXAL^TM^/P5P TD/Neurological indications TARDOXAL^TM^– On hold<br><br> <br>P5P - Regulatory and clinical planning underway 
| 14 |

| --- |

Management’sDiscussion and Analysis

Other Products

The Company is investing in the research and development of other new product development opportunities. The Company is also exploring opportunities to grow the business through acquisition. The Company has evaluated and continues to evaluate the acquisition or license of other approved commercial products with the objective of further broadening its product portfolio and generating additional revenue.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The preparation of the Company’s condensed consolidated interim financial statements for the three and nine months ended September 30, 2020 in conformity with IFRS requires management to make estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, revenue and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

Areas where management has made critical judgments in the process of applying accounting policies and that have the most significant effect on the amounts recognized in the consolidated financial statements include the determination of the Company’s and its subsidiaries’ functional currencies.

Information about key assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment to the carrying amount of assets and liabilities within the next financial year are included in the following notes to the consolidated financial statements for the year ended December 31, 2019:

· The valuation of the investment in Sensible Medical
· The valuation of the royalty obligation
--- ---
· The provisions for returns, chargebacks, rebates and discounts
--- ---
· The measurement of intangible assets
--- ---
· The measurement of the amount and assessment of the recoverability of income tax assets and income<br>tax provisions
--- ---

Valuation of financial instruments

Financial Assets

Initial recognition and measurement

Upon recognition of a financial asset, classification is made based on the business model for managing the asset and the asset’s contractual cash flow characteristics. The financial asset is initially recognized at its fair value and subsequently classified and measured as (i) amortized cost; (ii) fair value through other comprehensive income (“FVOCI”); or (iii) fair value through profit or loss (“FVTPL”). Financial assets are classified as FVTPL if they have not been classified as measured at amortized cost or FVOCI. Upon initial recognition of an equity instrument that is not held-for-trading, the Company may irrevocably designate the presentation of subsequent changes in the fair value of such equity instrument as FVTPL

Subsequent measurement

The subsequent measurement of financial assets depends on their classification as follows:

Financial assets measured at amortized cost

A financial asset is subsequently measured at amortized cost, using the effective interest method and net of any impairment allowance, if the asset is held within a business whose objective is to hold assets in order to collect contractual cash flows; and the contractual terms of the financial asset give rise, on specified dates, to cash flows that are solely payments of principal and interest. Cash and cash equivalents, short-term investments and accounts receivable are classified within this category.

Financial assets at FVTPL

Financial assets measured at FVTPL are carried in the statement of financial position at fair value with changes in fair value therein recognized in the statement of net (loss) income. The holdback receivable was classified within this category.

| 15 |

| --- |

Management’sDiscussion and Analysis

Financial assets at FVOCI

Financial assets measured at FVOCI are carried in the statement of financial position at fair value with changes in fair value therein recognized in the statement of comprehensive (loss) income. The Investment in Sensible Medical was classified within this category.

Derecognition

A financial asset or, where applicable a part of a financial asset or part of a group of similar financial assets is derecognized when the contractual rights to receive cash flows from the asset have expired; or the Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a ‘pass-through’ arrangement; and either (a) the Company has transferred substantially all the risks and rewards of the asset, or (b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

Financial liabilities

Initial recognition and measurement

The Company recognizes a financial liability on the trade date in which it becomes a party to the contractual provisions of the instrument at fair value plus any directly attributable costs. Financial liabilities are subsequently measured at amortized cost or FVTPL, and are not subsequently reclassified. The Company’s financial liabilities are accounts payable and accrued liabilities, royalty obligation and acquisition payable which are recognized on an amortized cost basis.

The royalty obligation was recorded at its fair value at the date at which the liability was incurred and subsequently measured at amortized cost using the effective interest rate method at each reporting date. Estimating fair value for this liability required determining the most appropriate valuation model which was dependent on its underlying terms and conditions. This estimate also required determining expected revenue from AGGRASTAT^®^ sales and an appropriate discount rate and making assumptions about them.

The acquisition payable was recorded at its fair value at the date at which the liability was incurred and subsequently measured at amortized cost using the effective interest rate method at each reporting date. Estimating fair value for this liability required determining an appropriate discount rate.

Offsetting of financial instruments

Financial assets and financial liabilities are offset, and the net amount reported in the statement of financial position if, and only if, there is a currently enforceable legal right to offset the recognized amounts and there is an intention to settle on a net basis, or to realize the assets and settle the liabilities simultaneously.

Fair value of financial instruments

Fair value is determined based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value is measured using the assumptions that market participants would use when pricing an asset or liability. Typically, fair value is determined by using quoted prices in active markets for identical or similar assets or liabilities. When quoted prices in active markets are not available, fair value is determined using valuation techniques that maximize the use of observable inputs. When observable valuation inputs are not available, significant judgement is required through determining the valuation technique to apply, the valuation techniques such as discounted cash flow analysis and selecting inputs. The use of alternative valuation techniques or valuation inputs may result in a different fair value.

Transaction costs

Transaction costs for all financial instruments measured at amortized cost, the transaction costs are included in the initial measurement of the financial asset or financial liability and are amortized using the effective interest rate method over a period that corresponds with the term of the financial instruments. Transaction costs for financial instruments classified as FVTPL are recognized as an expense in professional fees, in the period the cost was incurred.

| 16 |

| --- |

Management’sDiscussion and Analysis

Embedded Derivatives

For financial liabilities measured at amortized cost, under certain conditions, an embedded derivative must be separated from its host contract and accounted for as a derivative. An embedded derivative causes some or all of the cash flows that otherwise would be required by the contract to be modified according to a specified interest rate, financial instrument price, commodity price, foreign exchange rate, index of prices or rates, a credit rating or credit index, or other variable, provided in the case of a non-financial variable that the variable is not specific to a party to the contract. For financial assets at FVTPL, any embedded derivatives are not separated from its host contract.

Provision for returns, chargebacks,rebates and discounts

The Company has four commercially available products that generated revenue for the three months ended March 31, 2020, AGGRASTAT®, ZYPITAMAG™, ReDS^TM^and SNP (the “Products”) which it sells to United States customers. AGGRASTAT®, ZYPITAMAG™ and SNP are sold to wholesalers for resale; with AGGRASTAT® and SNP primarily being sold by the wholesalers to hospitals, while ZYPITAMAG™ is primarily sold by wholesalers to pharmacies. The Company sold ReDS^TM^directly to end users. Revenue from the sale of AGGRASTAT®, ZYPITAMAG™ and SNP is recognized upon the receipt of goods by the wholesaler, the point in time in which title and control of the transferred goods pass from the Company to the wholesale customer. At this point in time, the wholesaler has gained the sole ability to route the goods, and there are no unfulfilled obligations that could affect the wholesaler’s acceptance of the goods. Delivery of the product occurs when the goods have been received at the wholesaler in accordance with the terms of the sale. Revenue from the sale of ReDS^TM^ is recognized upon the receipt of goods by the end user, the point in time in which title and control of the transferred goods pass from the Company to the customer. At this point in time, the customer has gained the sole ability to benefit from the product, and there are no unfulfilled obligations that could affect the customer’s acceptance of the goods. Delivery of the product occurs when the goods have been shipped to the customer and the customer has accepted the products in accordance with the terms of the sale.

Sales are made subject to certain discounts available for prompt payment, volume discounts, rebates or chargebacks. Revenue from these sales is recognized based on the price specified per the pricing terms of the sales invoices, net of the estimated discounts, rebates or chargebacks. Variable consideration is based on historical information, using the expected value method. Revenue is only recognized to the extent that it is highly probable that a significant reversal will not occur. A liability is included within accounts payable and accrued liabilities and is measured for expected payments that will be made to the customers for the discounts in which they are entitled. Sales do not contain an element of financing as sales are made with credit terms within the normal operating cycle of the date of the invoice, which is consistent with market practice.

The measurement of intangible assets

Intangible assets that are acquired separately are measured at cost less accumulated amortization and accumulated impairment losses. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other expenditures are recognized in profit or loss as incurred.

Licenses are amortized on a straight-line basis over the contractual term of the acquired license. Patents and drug approvals are amortized on a straight-line basis over the legal life of the respective patent, ranging from five to twenty years, or its economic life, if shorter. Trademarks are amortized on a straight-line basis over the legal life of the respective trademark, being ten years, or its economic life, if shorter. Customer lists are amortized on a straight-line basis over approximately twelve years, or its economic life, if shorter.

Amortization on licenses commences when the intangible asset is available for use, which would typically be in connection with the commercial launch of the associated product under the license.

Following initial recognition, intangible assets are carried at cost less accumulated amortization and accumulated impairment losses. The cost of servicing the Company's patents and trademarks are expensed as incurred.

The amortization method and amortization period of an intangible asset with a finite useful life are reviewed at least annually. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates in the consolidated statements of net (loss) income and comprehensive (loss) income.

The measurement of the amount andassessment of the recoverability of income tax assets

The Company and its subsidiaries are generally taxable under the statutes of their country of incorporation.

| 17 |

| --- |

Management’sDiscussion and Analysis

Income tax expense comprises current and deferred taxes. Current taxes and deferred taxes are recognized in profit or loss except to the extent that they relate to a business combination, or items recognized directly in equity or in other comprehensive income.

Current taxes are the expected tax receivable or payable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax receivable or payable in respect of previous years.

The Company follows the liability method of accounting for deferred taxes. Under this method, deferred taxes are recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred taxes are not recognized for the following temporary differences: the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss, and differences relating to investments in subsidiaries and jointly controlled entities to the extent that it is probable that they will not reverse in the foreseeable future. In addition, deferred taxes are not recognized for taxable temporary differences arising on the initial recognition of goodwill. Deferred taxes are measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the tax laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax assets and liabilities, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax assets and liabilities on a net basis or their tax assets and liabilities will be realized simultaneously.

A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized.

The Company has provided for income taxes, including the impacts of tax legislation in various jurisdictions, in accordance with guidance issued by accounting regulatory bodies, the Canada Revenue Agency, the U.S. Internal Revenue Service, the Barbados Revenue Authority, the Mauritius Revenue Authority, as well as other state and local governments through the date of the issuance of these consolidated financial statements. Additional guidance and interpretations can be expected and such guidance, if any, could impact future results. While management continues to monitor these matters, the ultimate impact, if any, as a result of the application of any guidance issued in the future cannot be determined at this time.

The Company and its subsidiaries file federal income tax returns in Canada, the United States, Barbados and other foreign jurisdictions, as well as various provinces and states in Canada and the United States, respectively. The Company and its subsidiaries have open tax years, primarily from 2010 to 2019, with significant taxing jurisdictions, including Canada, the United States and Barbados. These open years contain certain matters that could be subject to differing interpretations of applicable tax laws and regulations and tax treaties, as they relate to the amount, timing or inclusion of revenues and expenses, or the sustainability of income tax positions of the Company and its subsidiaries. Certain of these tax years may remain open indefinitely.

Tax benefits acquired as part of a business combination, but not satisfying the criteria for separate recognition at that date, would be recognized subsequently if information about facts and circumstances changed. The adjustment would either be treated as a reduction to goodwill if it occurred during the measurement period or in profit or loss, when it occurs subsequent to the measurement period.

SELECTED FINANCIAL INFORMATION

It is important to note that historical patterns of expenditures cannot be taken as an indication of future expenditures. The amount and timing of expenditures and therefore liquidity and capital resources vary substantially from period to period depending on the results of commercial operations, development projects and/or the preclinical and clinical studies being undertaken at any one time and the availability of funding from investors and prospective commercial partners. The selected financial information provided below is derived from the Company's unaudited quarterly condensed consolidated interim financial statements for each of the last eight quarters. All information is presented under IFRS.

| 18 |

| --- |

Management’sDiscussion and Analysis

(in thousands of CDN, except per share data) June 30, 2020 March 31, 2020 December 31, 2019
Revenue, net 3,549 $ 2,676 $ 3,010 $ 3,473
Cost of goods sold (1,363 ) (1,476 ) (1,542 ) (3,385 )
Selling (923 ) (971 ) (2,069 ) (2,603 )
General and administrative (1,264 ) (770 ) (800 ) (647 )
Research and development (737 ) (98 ) (858 ) (1,271 )
Revaluation of holdback receivable — — — (3,623 )
Impairment of intangible assets — — — (6,321 )
Finance (expenses) income, net (99 ) 380 (73 ) 627
Foreign exchange gain (loss), net (210 ) 278 868 (1,477 )
Income (loss) for the period (1,047 ) 19 (1,464 ) (15,474 )
Basic loss per share (0.10 ) $ — $ (0.14 ) $ (1.08 )
Diluted loss per share (0.10 ) $ — $ (0.14 ) $ (1.08 )
(in thousands of CDN, except per share data) September 30, 2019 June 30, 2019 March 31, 2019 December 31, 2018
Revenue, net 5,519 $ 6,301 $ 4,880 $ 7,895
Cost of goods sold (1,496 ) (1,353 ) (1,038 ) (1,188 )
Selling (3,349 ) (3,319 ) (4,128 ) (4,698 )
General and administrative (1,044 ) (769 ) (935 ) (1,136 )
Research and development (976 ) (1,181 ) (921 ) (3,302 )
Revaluation of holdback receivable — — — (1,473 )
Impairment of intangible assets — — — —
Finance income, net 116 182 190 718
Foreign exchange (loss) gain, net 601 (813 ) (881 ) 5,341
(Loss) income for the period (599 ) (957 ) (2,756 ) 1,517
Basic (loss) earnings per share (0.04 ) $ (0.06 ) $ (0.18 ) $ 0.10
Diluted (loss) earnings per share (0.04 ) $ (0.06 ) $ (0.18 ) $ 0.09

All values are in US Dollars.

Net loss for the three-month period ended September 30, 2020 totaled $1,047 compared to a net loss of $599 for the three months ended September 30, 2019. Significant variances are as follows:

· A decrease in net revenues from commercial products of $1,970 resulting<br>from higher discounting pertaining to AGGRASTAT^®^as a result of increased<br>pricing pressure from competitors and decreases in the volume of the product sold including a reduction in procedures being<br>performed partially as a result of COVID 19.
· Net foreign exchange losses of $210 for the three months ended September 30, 2020 compared to foreign<br>exchange gains of $601 for the three months ended September 30, 2019 as a result of the impact of changes in the value of the Canadian<br>dollar against the U.S. dollar on U.S. dollar denominated cash and short-term investments being held by the Company.
--- ---
· An increase in general and administration expenses of $220 primarily due to increased legal costs<br>associated with the patent challenge litigation being incurred during the three months ended September 30, 2020.
--- ---

Partially offset by:

· A decrease of $2,426 in selling expenses primarily as a result of cost reductions implemented during<br>late 2019 and throughout 2020 as well as decreases in costs as a result of limitations to conference and travel related costs due<br>to COVID-19. 
| 19 |

| --- |

Management’sDiscussion and Analysis

· A decrease of $239 in research and developments expenses primarily as a result of the timing of<br>research and development expenditures resulting in the timing of each development project.

RESULTS OF OPERATIONS

Revenue

The change in revenue for the three and nine months ended September 30, 2020 and 2019 is reflected in the following table:

(in thousands of CDN $) Three months<br> <br>ended<br> <br>September 30, 2020 Three months <br><br>ended <br><br>September 30, <br><br>2019 Increase (Decrease) Nine months<br> <br>Ended<br> <br>September 30, 2020 Nine months<br><br> ended <br><br>September 30,<br><br> 2019 Increase (Decrease)
AGGRASTAT^®^ revenue, net $ 3,439 $ 5,324 $ (1,885 ) $ 8,722 $ 16,341 $ (7,619 )
ZYPITAMAG revenue, net 105 78 27 371 87 284
ReDS^TM^revenue, net — 117 (117 ) 89 272 (183 )
SNP revenue, net 5 — 5 53 — 53
$ 3,549 $ 5,519 $ (1,970 ) $ 9,235 $ 16,700 $ (7,465 )

Net AGGRASTAT^®^ product sales for three and nine months ended September 30, 2020 were $3,439 and $8,722, respectively, compared to $5,324 and $16,341, respectively, during the three and nine months ended September 30, 2019.

The Company primarily sells finished AGGRASTAT^®^ to drug wholesalers. These wholesalers subsequently sell AGGRASTAT^®^to hospitals where health care providers administer the drug to patients. Wholesaler management decisions to increase or decrease their inventory of AGGRASTAT^®^may result in sales of AGGRASTAT^®^to wholesalers that do not track directly with demand for the product at hospitals. The Company has set up a portal called Medicure Direct to market the Company’s branded and generic products directly to hospitals and pharmacies with initial sales expected to occur in the fourth quarter of 2020 through this initiative.

Hospital demand for AGGRASTAT^®^ has been lower during the first nine months of 2020 when compared to the prior year, however the number of hospital customers using AGGRASTAT^®^ continued to remain strong leading to patient market share held by the product of approximately 65% as of September 30, 2020. The Company's commercial team continues to work on expanding its customer base, however this continued increase in the customer base for AGGRASTAT^®^ has not directly resulted in corresponding revenue increases as the Company continues to face increased competition resulting from further genericizing of the Integrilin market which has created pricing pressures on AGGRASTAT^®^ combined with lower hospital demand for the product including a reduction in procedures being performed as a result of COVID 19. The Company continues to expect strong patient market share despite reduced revenue from the AGGRASTAT^®^ brand and diversifying revenues away from a single product became increasingly important to the Company.

All of the Company’s sales are denominated in U.S. dollars and the U.S. dollar improved in value against the Canadian dollar during the three and nine months ended September 30, 2020 when compared to the three and nine months ended September 30, 2019. This led to increased AGGRASTAT^®^revenues, however this was offset by the increasing price pressures facing AGGRASTAT^®^ when comparing the two periods as well as decreases in demand.

Net ZYPITAMAG^TM^ product sales for three and nine months ended September 30, 2020 were $105 and $371, respectively, compared to $78 and $87, respectively, for the three and nine months ended September 30, 2020.

The Company primarily sells ZYPITAMAG^TM^ to drug wholesalers. These wholesalers subsequently sell ZYPITAMAG^TM^to pharmacies who in turn sell the product to patients. The Company expects ZYPITAMAG^TM^ revenues to grow throughout 2020 and beyond. Beginning in the second quarter, the Company launched a direct to patient online pharmacy program which resulted in sales of ZYPITAMAG^TM^being made directly to pharmacy customers.

During the three and nine months ended September 30, 2020, ReDS^TM^ contributed revenue of nil and $89, respectively, from the sale of the product in the United States compared to $117 and $272, respectively, for the three and nine months ended September 30, 2019.

| 20 |

| --- |

Management’sDiscussion and Analysis

The Company recorded initial sales during the three and nine months ended September 30, 2020 totaling $5 and $53, respectively, from SNP which recently became available in the US market in late 2019. The Company primarily sells finished SNP to drug wholesalers. These wholesalers subsequently sell SNP to hospitals where health care providers administer the drug to patients. Wholesaler management decisions to increase or decrease their inventory of SNP may result in sales of SNP to wholesalers that do not track directly with demand for the product at hospitals. The Company has set up a portal called Medicure Direct to market the Company’s branded and generic products directly to hospitals and pharmacies with initial sales expected to occur in the fourth quarter of 2020 through this initiative.

Cost of goods sold

The change in cost of goods sold for the three and nine months ended September 30, 2020 and 2019 is reflected in the following table:

(in thousands of CDN $) Three months ended<br> <br>September 30, 2020 Three months <br><br>ended <br><br>September 30, <br><br>2019 Increase (Decrease) Nine months<br> <br>Ended<br> <br>September 30, 2020 Nine months<br><br> ended <br><br>September 30, <br><br>2019 Increase (Decrease)
AGGRASTAT^®^ $ 733 $ 662 $ 71 $ 2,113 $ 2,626 $ (513 )
ZYPITAMAG^TM^ 625 660 (35 ) 2,007 794 1,213
ReDS^TM^ — 174 (174 ) — 467 (467 )
SNP 5 — 5 261 — 261
$ 1,363 $ 1,496 $ (133 ) $ 4,381 $ 3,887 $ 494

Cost of goods sold represents direct product costs associated with AGGRASTAT^®^, ZYPITAMAG^TM^, ReDS^TM^and SNP, including write-downs for obsolete inventory, amortization of the related intangible assets and royalties paid on ZYPITAMAG^TM^.

AGGRASTAT^®^ cost of goods sold for the three and nine months ended September 30, 2020 were $733 and $2,113, respectively, compared to $662 and $2,626, respectively, for the three and nine months ended September 30, 2019. The increase in cost of goods sold is the result of the product mix of AGGRASTAT^®^product sold during the three months ended September 30, 2020 when compared to the same period in the prior year. The decrease in cost of goods sold is the result of lower volume of AGGRASTAT^®^product sold during the nine months ended September 30, 2020 when compared to the same period in the prior year.

ZYPITAMAG^TM^ cost of goods sold for the three months ended September 30, 2020 totaled $625 and includes $19 relating to product sold to the Company’s wholesale customers, $603 from amortization of the ZYPITAMAG^TM^ intangible assets and $3 relating to royalties on the sale of ZYPITAMAG^TM^resulting from the acquisition of the product in September of 2019. This compares to ZYPITAMAG^TM^ cost of goods sold for the three months ended September 30, 2019 of $660 which was the result of $16 relating to product sold to the Company’s wholesale customers, $66 relating to amortization of the ZYPITAMAG^TM^ license and $578 relating to a write-down of expired inventory.

ZYPITAMAG^TM^ cost of goods sold for the nine months ended September 30, 2020 totaled $2,007 and includes $54 relating to product sold to the Company’s wholesale customers, $1,838 from amortization of the ZYPITAMAG^TM^ intangible assets, $104 relating to a write-down of expired inventory and $11 relating to royalties on the sale of ZYPITAMAG^TM^resulting from the acquisition of the product in September of 2019. This compares to ZYPITAMAG^TM^ cost of goods sold for the nine months ended September 30, 2019 of $794 which was the result of $17 relating to product sold to the Company’s wholesale customers, $199 relating to amortization of the ZYPITAMAG^TM^ license and $578 relating to a write-down of expired inventory.

There was no cost of goods sold relating to the ReDS^TM^ product recorded during the three and nine months ended September 30, 2020. ReDS^TM^ cost of goods sold for the three and nine months ended September 30, 2019 totaled $174 and $467, respectively, and related to the amortization of the ReDS^TM^ license, which was recorded on the statement of financial position within intangible assets prior to the impairment recorded over the ReDS^TM^intangible assets.

| 21 |

| --- |

Management’sDiscussion and Analysis

The cost of goods sold related to SNP totals $5 and $261, respectively, for the three and nine months ended September 30, 2020. For the three months ended September 30, 2020, the cost of goods sold totaling $5 related to product sold to the Company’s wholesaler customers. For the nine months ended September 30, 2020 totaled $261 and includes $53 relating to product sold to the Company’s wholesale customers and an impairment loss on the write-down of inventory of $208 as a result of reduced selling prices for the product experienced in the market pertaining to SNP relating to inventory received during the nine months ended September 30, 2020.

Selling

Selling expenses include salaries and related costs for those employees involved in the commercial operations of the Company, as well as costs associated with marketing, promotion, distribution of the Company’s products as well as market access activities and other commercial activities. The expenditures are required to support sales and marketing efforts of AGGRASTAT^®^, ZYPITAMAG^TM^, ReDS^TM^ and SNP.

The changes in selling expenditures for the three and nine months ended September 30, 2020 and 2019 is reflected in the following table:

(in thousands of CDN $) Three months<br> <br>ended<br> <br>September 30, 2020 Three months <br>ended <br>September 30, <br>2019 Increase (Decrease) Nine months<br> <br>Ended<br> <br>September 30, 2020 Nine months<br><br> ended <br>September 30,<br> 2019 Increase (Decrease)
Selling $ 923 $ 3,349 $ (2,426 ) $ 3,963 $ 10,796 $ (6,833 )

Selling expenses for the three and nine months ended September 30, 2020 were $923 and $3,963, respectively, compared to $3,349 and $10,796, respectively, for the three and nine months ended September 30, 2019.

Commercial sales expenses decreased during the three and nine months ended September 30, 2020 as compared to the same periods in the prior year due to commercial launch costs relating to ReDS^TM^ being incurred during the three and nine months ended September 30, 2019 and as a result of cost reductions implemented during late 2019 and throughout 2020 as well as decreases in costs as a result of limitations to conference and travel related costs due to COVID-19.

During the three and nine months ended September 30, 2020, the Company recorded a recovery of salary expenditures of $311 and $559, respectively, through government assistance resulting from the Canada Emergency Wage Subsidy within selling expenses.

General and administrative

General and administrative expenses include the cost of administrative salaries, ongoing business development and corporate stewardship activities and professional fees such as legal, audit, investor and public relations.

The changes in general and administrative expenditures for the three and nine months ended September 30, 2020 and 2019 is reflected in the following table:

(in thousands of CDN $) Three months<br> <br>ended<br> <br>September 30, 2020 Three months <br>ended<br> September 30, 2019 Increase (Decrease) Nine months<br> <br>Ended<br> <br>September 30, 2020 Nine months <br> ended <br>September 30, 2019 Increase (Decrease)
General and administrative $ 1,264 $ 1,044 $ 220 $ 2,834 $ 2,748 $ 86

General and administrative expenses for the three and nine months ended September 30, 2020 were $1,264 and $2,834, respectively, compared to $1,044 and $2,748, respectively, for the three and nine months ended September 30, 2019. General and administration expenses increased during the three and nine months ended September 30, 2020 when compared to the three and nine months ended September 30, 2019. The increase in general and administrative expenses is primarily related to cost reductions implemented by the Company during late 2019 throughout 2020 partially offset by higher legal costs associated with the Company’s ongoing patent challenge during the nine months ended September 30, 2020 as compared to the nine months ended September 30, 2019.

| 22 |

| --- |

Management’sDiscussion and Analysis

During the three and nine months ended September 30, 2020, the Company recorded a recovery of salary expenditures of $52 and $95, respectively, through government assistance resulting from the Canada Emergency Wage Subsidy within general and administrative expenses.

Research and Development

Research and development expenditures include costs associated with the Company’s clinical development and preclinical programs including salaries, monitoring and other research costs. The Company expenses all research costs and has not had any development costs that meet the criteria for capitalization under IFRS. Prepaid research and development costs represent advance payments under contractual arrangements for clinical activity outsourced to research centers.

The change in research and development expenditures for the three and nine months ended September 30, 2020 and 2019 is reflected in the following table:

(in thousands of CDN $) Three months<br> <br>ended<br> <br>September 30, 2020 Three months <br>ended <br>September 30,<br> 2019 Increase (Decrease) Nine months<br> <br>Ended<br> <br>September 30, 2020 Nine months<br><br> ended <br>September 30,<br><br> 2019 Increase (Decrease)
Research and development $ 737 $ 976 $ (239 ) $ 1,693 $ 3,078 $ (1,385 )

Net research and development expenditures for the three and nine months ended September 30, 2020 totaled $737 and $1,693, respectively, compared to $976 and $3,078, respectively for the three and nine months ended September 30, 2019. Research and development expenditures include costs associated with the Company’s on-going AGGRASTAT^®^ development, clinical development and preclinical programs including salaries, research centered costs and monitoring costs, as well as research and development costs associated with the development projects being undertaken to develop additional cardiovascular products. The decrease experienced during the three and nine months ended September, 2020 when compared to the three and nine months ended September 30, 2019 is primarily a result of FDA refunds obtained by the Company during 2020 resulting in a recovery of expenses of $677 pertaining to previously paid FDA fees as well as reducing the quarterly expense going forward as well as timing of research and development expenditures resulting in the timing of each development project.

During the three and nine months ended September 30, 2020, the Company recorded a recovery of salary expenditures of $41 and $75, respectively, through government assistance resulting from the Canada Emergency Wage Subsidy within research and development expenses.

Finance Income (expense), Net

The change in finance income (expense), net for the three and nine months ended September 30, 2020 and 2019 is reflected in the following table:

(in thousands of CDN $) Three months<br> <br>ended<br> <br>September 30, 2020 Three months <br>ended <br>September 30, 2019 Increase (Decrease) Nine months<br> <br>Ended<br> <br>September 30, 2020 Nine months ended <br>September 30, 2019 Increase (Decrease)
Finance income (expense), net $ (99 ) $ 116 $ (215 ) $ 208 $ 488 $ (280 )

The finance expense for the three months ended September 30, 2020 of $99 is a result of accretion on the Company’s AGGRASTAT^®^royalty obligation, accretion on the ZYPITAMAG^TM^ acquisition payable, finance expense related to the Company’s lease obligations and bank charges. This compares to finance income for the three months ended September 30, 2019 which pertains to interest income on funds held by the Company, partially offset by accretion on the Company’s AGGRASTAT^®^royalty obligation, accretion on the ZYPITAMAG^TM^ acquisition payable, finance expense related to the Company’s lease obligations and bank charges.

| 23 |

| --- |

Management’sDiscussion and Analysis

The finance income for the nine months ended September 30, 2020 relates to interest earned on funds held and a recovery of accretion on the Company’s AGGRASTAT^®^royalty obligation, partially offset by accretion on the ZYPITAMAG^TM^ acquisition payable, finance expense related to the Company’s lease obligations and bank charges, The decrease for the nine months ended September 30, 2020 when compared to the nine months ended September 30, 2019 is a result of higher interest on cash held by the Company due to higher cash levels during the first half of 2019 when compared to the same period in 2020.

Foreign Exchange Gain (Loss), Net

The change in foreign exchange gain (loss), net for the three and nine months ended September 30, 2019 and 2018 is reflected in the following table:

(in thousands of CDN $) Three months<br> <br>ended<br> <br>September 30, 2020 Three months <br>ended <br>September 30, 2019 Increase (Decrease) Nine months<br> <br>Ended<br> <br>September 30, 2020 Nine months ended <br>September 30, 2019 Increase (Decrease)
Foreign exchange gain (loss), net $ (210 ) $ 601 $ (811 ) $ 936 $ (1,093 ) $ 2,029

The foreign exchange loss of $210 for the three months ended September 30, 2020 compares to a foreign exchange gain of $601 for the three months ended September 30, 2019. The foreign exchange gain of $936 for the nine months ended September 30, 2020 compares to a foreign exchange loss of $1,093 for the nine months ended September 30, 2019. The changes to foreign exchange gains and losses results from changes in the US dollar exchange rate during the respective periods, which led to the foreign exchange gains and losses as it applies to the significant US dollar cash balances held by the Company as at the end of both periods.

Income Tax Recovery

The change in income tax recovery (expense) for the three and nine months ended September 30, 2020 and 2019 is reflected in the following table:

(in thousands of CDN $) Three months<br> <br>ended<br> <br>September 30, 2020 Three months <br>ended <br>September 30, 2019 Increase (Decrease) Nine months<br> <br>Ended<br> <br>September 30, 2020 Nine months ended <br>September 30, 2019 Increase (Decrease)
Income tax recovery (expense) $ — $ 30 $ (30 ) $ — $ 102 $ (102 )

The income tax recovery of $30 and $102, respectively, during the three and nine months ended September 30, 2019 is primarily related activities in the United States from the Company’s commercial business during the period. The Company did not record any income tax expense or recovery during the three and nine months ended September 30, 2020.

Loss and comprehensive loss

The consolidated net loss and comprehensive loss for the three and nine months ended September 30, 2020 and 2019 is reflected in the following table:

(in thousands of CDN $) Three months<br> <br>ended<br> <br>September 30, 2020 Three months <br>ended <br>September 30, 2019 Increase (Decrease) Nine months<br> <br>Ended<br> <br>September 30, 2020 Nine months ended <br>September 30, 2019 Increase (Decrease)
Net Loss $ (1,047 ) $ (599 ) $ (448 ) $ (2,492 ) $ (4,312 ) $ 1,820
Comprehensive Loss (1,319 ) (616 ) (703 ) (2,531 ) (6,061 ) 3,530
Basic loss per share (0.10 ) (0.04 ) (0.06 ) (0.23 ) (0.28 ) 0.05
Diluted loss per share $ (0.10 ) $ (0.04 ) $ (0.06 ) $ (0.23 ) $ (0.28 ) $ 0.05 
| 24 |

| --- |

Management’sDiscussion and Analysis

For the three months ended September 30, 2020, the Company recorded net loss of $1,047 or $0.10 per share ($0.10 per share diluted) compared to a net loss of $599 or $0.04 per share ($0.04 per share diluted) for the three months ended September 30, 2019. As discussed above, the main factors contributing to the increase in the net loss were the lower revenues, increase in general and administrative expenses and the loss from foreign exchange experienced during the three months ended September 30, 2020 when compared to the three months ended September 30, 2019.

For the nine months ended September 30, 2020, the Company recorded a net loss of $2,492 or $0.23 per share ($0.23 per share diluted) compared to $4,312 or $0.28 per share ($0.28 per share diluted) for the nine months ended September 30, 2019. As discussed above, the main factors contributing to the reduction in the net loss were the reduction of selling expenses, the gain from foreign exchange experienced and reduced research and development expenses resulting from a refund of FDA fees previously paid during the nine months ended September 30, 2020, partially offset by lower revenues when compared to the nine months ended September 30, 2019.

For the three and nine months ended September 30, 2020, the Company recorded a total comprehensive loss of $1,319 and $2,531, respectively, compared to $616 and $6,061, respectively, for the three and nine months ended September 30, 2019. The change in comprehensive loss results from the factors described above as well as fluctuations in the US dollar exchange rate during the periods.

The weighted average number of common shares outstanding used to calculate basic and diluted loss per share for the three and nine months ended September 30, 2020 was 10,662,313 and 10,739,369, respectively. The weighted average number of common shares outstanding used to calculate basic and diluted loss per share for the three and nine months ended September 30, 2019 was 14,888,656 and 15,239,918, respectively.

As at September 30, 2020, the Company had 10,662,313 common shares outstanding, 900,000 warrants to purchase common shares and 1,364,958 stock options, of which 1,101,358 were exercisable, to purchase common shares outstanding. As at November 10, 2020, the Company had 10,451,313 common shares outstanding, 900,000 warrants to purchase common shares and 1,364,958 stock options, of which 1,101,358 were exercisable, to purchase common shares outstanding.

Earnings before interest, taxes, depreciationand amortization (EBITDA)

The Company defines EBITDA as "earnings before interest, taxes, depreciation, amortization and other income or expense" and Adjusted EBITDA as “EBITDA adjusted for non-cash and non-recurring items”. The terms "EBITDA" and “Adjusted EBITDA”, as it relates to the three and nine months ended September 30, 2020 and 2019 results prepared using IFRS, do not have any standardized meaning according to IFRS. It is therefore unlikely to be comparable to similar measures presented by other companies. EBITDA and Adjusted EBITDA for the three and nine months ended September 30, 2020 and 2019 is reflected in the following table:

(in thousands of CDN $) Three months<br> <br>ended<br> <br>September 30, 2020 Three months <br>ended <br>September 30, 2019 Increase (Decrease) Nine months<br> <br>Ended<br> <br>September 30, 2020 Nine months ended <br>September 30, 2019 Increase (Decrease)
Operating income $ (738 ) $ (1,346 ) $ 608 $ (3,635 ) $ (3,809 ) $ 174
Add: Amortization expense 677 341 336 2,062 1,019 1,043
EBITDA (61 ) (1,005 ) 944 (1,573 ) (2,790 ) 1,217
Add: <br>Stock-based compensation 65 108 (43 ) 311 280 31
Write-down of inventory — 578 (578 ) 239 578 (339 )
Adjusted EBITDA $ 4 $ (319 ) $ (323 ) $ (1,023 ) $ (1,932 ) $ 909

EBITDA for the three months ended September 30, 2020 was ($61) compared to EBITDA of ($1,005) for the three months ended September 30, 2019, EBITDA for the nine months ended September 30, 2020 was ($1,573) compared to EBITDA of ($2,790) for the nine months ended September 30, 2019.

Adjusted EBITDA for the three months ended September 30, 2020 was $4 compared to adjusted EBITDA of (319) for the three months ended September 30, 2019, Adjusted EBITDA for the nine months ended September 30, 2020 was ($1,023) compared to adjusted EBITDA of ($1,932) for the nine months ended September 30, 2019.

| 25 |

| --- |

Management’sDiscussion and Analysis

As discussed above the main factor contributing to the change in EBITDA was the decrease in expenses experienced throughout 2020, partially offset by decreases in revenues when compared to the same periods of 2019.

LIQUIDITY AND CAPITAL RESOURCES

Since the Company’s inception, it has financed operations primarily from net revenue received from the sale of AGGRASTAT^®^, ZYPITAMAG^TM^, ReDS^TM^and SNP, the sale of its equity securities, the issue and subsequent exercises of warrants and stock options, interest on excess funds held and the issuance of debt.

On October 3, 2017, the Company announced the completion of the Apicore Sale Transaction to the Buyer. Under the Apicore Sale Transaction, the Company received net proceeds of approximately US$105,000 of which approximately US$55,000 was received on October 3, 2017, with the remainder received in early 2018. There is also a holdback receivable of US$10,000 that was due in 2019. These funds received and yet to be received by the Company were after payment of all transaction costs, the compensation paid to holders of Apicore’s employee stock options, the redemption of the remaining shares of Apicore not owned by Medicure and other adjustments.

On February 1, 2018, the Company announced that it had received the deferred purchase price proceeds of approximately US$50,000 from the Buyer as a result of the Apicore Sale Transaction. The US$50,000 was included in the total net proceeds of US$105,000 described earlier. The Company did not receive any contingent payments based on an earn out formula as certain financial results within the Apicore business were not met following the Apicore Sale Transaction.

On December 5, 2019, the Company announced that it had reached a settlement agreement with the purchaser of the Company’s interests in Apicore with respect to the amounts heldback under the Apicore sale agreement. A settlement agreement was reached under which Medicure received a net payment of US$5,100 in relation to the holdback receivable.

The funds received from the Apicore sales transaction were invested and used for business and product development purposes and to fund operations as needed as well as funding the purchase of common shares under the SIB completed by the Company in December of 2019.

Cash used in operating activities for the nine months ended September 30, 2020 was $1,051 compared to $10,854 for the comparable period in the prior year. The decrease in cash used in operating activities is primarily due to difference in changes in working capital between the two periods and the decreased net loss incurred during the nine months ended September 30, 2020.

The Company did not have any cash used in or from investing activities for the nine months ended September 30, 2020. Cash from investing activities for the nine months ended September 30, 2019 totaled $27,564 and related to $47,747 received from the redemptions of short-term investments, which was offset by the investment in Sensible Medical Innovations Ltd., which consisted of the acquisition of the investment of $6,337 and the acquisition of intangible assets of $7,038 and the acquisition of ZYPITAMAG^TM^which totaled $6,622. Additionally, $186 was spent of the acquisition of property and equipment during the nine months ended September 30, 2019.

Cash used in financing activities for the nine months ended September 30, 2020 totaled $154 and related to cash paid to acquire the Company’s common shares under its normal course issuer bid compared to $4,145 paid during the nine months ended September 30, 2019.

As at September 30, 2020, the Company had unrestricted cash totaling $11,871 compared to $12,965 as of December 31, 2019. As at September 30, 2020, the Company had working capital of $17,930 compared to $19,702 as at December 31, 2019.

During the year ended December 31, 2019, the Company repurchased and cancelled 751,800 (2018 – 441,400), common shares as a result of the 2018 NCIB and 2019 NCIB. The aggregate price paid for these common shares totaled $4,145 (2018 - $3,021). During the year ended December 31, 2019 the Company recorded $1,810 (2018 - $480) directly in its deficit representing the difference between the aggregate price paid for these common shares and a reduction of the Company’s share capital totaling $5,955 (2018 - $3,501).

During the three and nine months ended September 30, 2020, the Company repurchased and cancelled 141,700 common shares as a result of the 2019 NCIB. The aggregate price paid for these common shares totaled $154. During the three and nine months ended September 30, 2020, the Company recorded $978 directly in its deficit representing the difference between the aggregate price paid for these common shares and a reduction of the Company’s share capital totaling $1,132.

| 26 |

| --- |

Management’sDiscussion and Analysis

On June 29, 2020, the Company announced that the TSX-V accepted the Company's notice of its intention to make a normal course issuer bid (the "2020 NCIB"). Under the terms of the 2020 NCIB, the Company may acquire up to an aggregate of 533,116 common shares, representing five percent of the common shares outstanding at the time of the application, over the twelve-month period that the 2020 NCIB was in place. The 2020 NCIB commenced on June 30, 2020 and will end on June 29, 2021, or on such earlier date as the Company may complete its maximum purchases allowed under the 2020 NCIB.

Subsequent to September 30, 2020, the Company purchase 211,000 common shares for cancellation for a total cost of $205 to the Company.

On December 20, 2019, the Company completed a SIB pursuant to which the Company purchased 4,000,000 of its common shares for cancellation at a set purchase price of $6.50 per common share for a total purchase price of $26,000 in cash. The Company incurred an additional $139 on transaction costs related to the SIB for a total aggregate purchase price paid of $26,139. During the year ended December 31, 2019, the Company recorded $5,466 directly in its deficit representing the difference between the aggregate price paid for these common shares and a reduction of the Company’s share capital totaling $31,605.

The Company did not have any long-term debt recorded in its consolidated financial statements as at September 30, 2020.

CONTRACTUAL OBLIGATIONS

As at September 30, 2020, in the normal course of business, the Company has obligations to make future payments, representing contracts and other commitments that are known and committed as follows:

Contractual Obligations Payment Due by Period
(in thousands of CDN$) Total 2020 remaining 2021 2022 2023 2024 Thereafter
Accounts Payable and Accrued Liabilities $ 5,462 $ 5,462 $ — $ — $ — $ — $ —
Income Taxes Payable 474 474 — — — — —
Lease Obligation 1,052 60 238 238 238 238 40
Acquisition Payable 2,001 667 667 667 — — —
Purchase Agreement Commitments 4,355 1,333 1,311 1,311 200 200 —
Total $ 13,344 $ 7,996 $ 2,216 $ 2,216 $ 438 $ 438 $ 40

Payments in connection with the Company’s royalty obligation, as described below, are excluded from the table above.

Commitments

The Company has entered into a manufacturing and supply agreement to purchase a minimum quantity of AGGRASTAT^®^unfinished product inventory totaling $200 (US$150) annually (based on current pricing) until 2024 and a minimum quantity of AGGRASTAT^®^finished product inventory totaling $341 (€218) annually (based on current pricing) until 2022 and $821 (€525) annually (based on current pricing) until 2022.

Effective January 1, 2020, the Company renewed its business and administration services agreement with Genesys Venture Inc. (“GVI”), as described in note 11(b) to the Company’s condensed consolidated interim financial statements, under which the Company is committed to pay $7 per month or $85 per year for a one-year term.

Contracts with contract research organizations are payable over the terms of the associated agreements and clinical trials and timing of payments is largely dependent on various milestones being met, such as the number of patients recruited, number of monitoring visits conducted, the completion of certain data management activities, trial completion, and other trial related activities.

On October 31, 2017, the Company acquired an exclusive license to sell and market PREXXARTAN^®^ (valsartan) oral solution in the United States and its territories with a seven-year term, with extensions to the term available, which had been granted tentative approval by the FDA, and which was converted to final approval during 2017. The Company acquired the exclusive license rights for an upfront payment of US$100, with an additional US$400 payable on final FDA approval and will be obligated to pay royalties and milestone payments from the net revenues of PREXXARTAN^®^. The US$400 payment is on hold pending resolution of the dispute between the licensor and the third-party manufacturer of PREXXARTAN^®^and is recorded within accounts payable and accrued liabilities on the condensed consolidated interim statements of financial position.

| 27 |

| --- |

Management’sDiscussion and Analysis

On December 14, 2017 the Company acquired an exclusive license to sell and market ZYPITAMAG^TM^ in the United States and its territories for a term of seven years with extensions to the term available. The Company had entered into a profit-sharing arrangement resulting in a portion of the net profits from ZYPITAMAG^TM^ being paid to the licensor. No amounts are due and/or payable pertaining to profit sharing on this product and the profit-sharing arrangement was eliminated with the Company’s acquisition of ZYPITAMAG^TM^ on September 30, 2019 as described in note 5 of the Company’s condensed consolidated interim financial statements.

The Company periodically enters into research agreements with third parties that include indemnification provisions customary in the industry. These guarantees generally require the Company to compensate the other party for certain damages and costs incurred as a result of claims arising from research and development activities undertaken on behalf of the Company. In some cases, the maximum potential amount of future payments that could be required under these indemnification provisions could be unlimited. These indemnification provisions generally survive termination of the underlying agreement. The nature of the indemnification obligations prevents the Company from making a reasonable estimate of the maximum potential amount it could be required to pay. Historically, the Company has not made any indemnification payments under such agreements and no amount has been accrued in the condensed consolidated interim financial statements with respect to these indemnification obligations.

As a part of the Birmingham debt settlement, beginning on July 18, 2011, the Company is obligated to pay a royalty to Birmingham based on future commercial AGGRASTAT^®^ sales until May 1, 2023. The royalty is based on 4% of the first $2,000 of quarterly AGGRASTAT^®^ sales, 6% on the portion of quarterly sales between $2,000 and $4,000 and 8% on the portion of quarterly sales exceeding $4,000 payable within 60 days of the end of the preceding three-month periods ended February 28, May 31, August 31 and November 30. Birmingham has a one-time option to switch the royalty payment from AGGRASTAT^®^ to a royalty on the sale of MC-1. Management has determined there is no value to the option to switch the royalty to MC-1 as the product is not commercially available for sale and the extended long-term development timeline associated with commercialization of the product. Royalties for the three and nine months ended September 30, 2020 totaled $126 and $338, respectively, (2019 – $267 and $840) with payments made during the three and nine months ended September 30, 2020 of $nil and $326, respectively (2019 – $293 and $1,133).

Beginning with the acquisition of ZYPITAMAG^TM^, completed on September 30, 2019, the Company is obligated to pay royalties to Zydus subsequent to the acquisition date on net sales of ZYPITAMAG^TM^. During the three and nine months ended September 30, 2020, the Company recorded $3 and $11, respectively, in royalties in regards to ZYPITAMAG^TM^ which is recorded within cost of goods sold on the condensed consolidated interim statement of net (loss) income and comprehensive income. As at September 30, 2020, $6 (December 31, 2019 - $3) was recorded within accounts payable and accrued liabilities on the condensed consolidated interim statement of financial position in regards to these royalties.

The Company is obligated to pay royalties on any future net sales of PREXXARTAN^®^ to the licensor of PREXXARTAN^®^. To date, no royalties are due and/or payable.

In the normal course of business, the Company may from time to time be subject to various claims or possible claims. Although management currently believes there are no claims or possible claims that if resolved would either individually or collectively result in a material adverse impact on the Company’s financial position, results of operations, or cash flows, these matters are inherently uncertain and management’s view of these matters may change in the future.

During 2018, the Company was named in a civil claim in Florida from the third-party manufacturer of PREXXARTAN^®^against the licensor. The claim disputed the rights granted by the licensor to the Company with respect to PREXXARTAN^®^. The claim against the Company has since been withdrawn, however the dispute between the licensor and the third-party manufacturer continues.

On September 10, 2015, the Company submitted a supplemental New Drug Application (“sNDA”) to the FDA to expand the label for AGGRASTAT^®^. The label change is being reviewed and evaluated based substantially on data from published studies. If the label change submission were to be successful, the Company will be obligated to pay €300 over the course of a three-year period in equal quarterly instalments following approval. On July 7, 2016, the Company received a Complete Response Letter stating the sNDA cannot be approved in its present form and requested additional information. The payments are contingent upon the success of the filing and as such the Company has not recorded any amount in the condensed consolidated interim statements of net (loss) income and comprehensive loss pertaining to this contingent liability.

During 2015, the Company began a development project of a cardiovascular generic drug in collaboration with Apicore. The Company has entered into a supply and development agreement under which the Company holds all commercial rights to the drug. In connection with this project, the Company is obligated to pay Apicore 50% of net profit from the sale of this drug. On August 13, 2018, the Company announced that the FDA has approved its ANDA for SNP, a generic intravenous cardiovascular product and the product became available commercially during the third quarter of 2019. To date, no amounts are due and/or payable pertaining to profit sharing on this product.

| 28 |

| --- |

Management’sDiscussion and Analysis

FINANCIAL INSTRUMENTS

The Company is exposed to market risks related to changes in interest rates and foreign currency exchange rates. The carrying values of current monetary assets and liabilities approximate their fair values due to their relatively short periods to maturity. The royalty obligation and acquisition payable were recorded at their fair values at the date at which the liabilities were incurred and subsequently revalued using the effective interest method at each reporting date. Based on the cash and cash equivalent balances held by the Company at September 30, 2020, its results of operations or cash flows could be affected by a sudden change in market interest rates. Based on the Company’s exposures as at September 30, 2020, assuming that all other variables remain constant, a 1% appreciation or deterioration in interest rates would result in a corresponding increase or decrease, respectively on the Company's net loss of approximately $119 (2019

  • $130).

The Company has not entered into any futures or forward contracts as at September 30, 2020. The Company is exposed to foreign exchange rate changes that could have a material impact on the Company’s results. Foreign exchange risk is the risk that the fair value of future cash flows for financial instruments will fluctuate because of changes in foreign exchange rates. The Company is exposed to currency risks primarily due to its U.S dollar denominated cash and cash equivalents, accounts receivable, other assets, accounts payable and accrued liabilities, income taxes payable, royalty obligation and acquisition payable. The Company has not entered into any foreign exchange hedging contracts.

The Company is exposed to U.S. dollar currency risk through the following U.S. denominated monetary financial assets and liabilities:

(Expressed in U.S. Dollars) September 30, 2020 December 31, 2019
Cash and cash equivalents $                6,899 $         9,518
Accounts receivable 4,580 7,817
Other assets 20 30
Accounts payable and accrued liabilities (3,241) (6,714)
Income taxes payable (355) (398)
Current portion of royalty obligation (537) (671)
Current portion of acquisition payable (500) (500)
Royalty obligation (544) (906)
Acquisition payable (868) (1,275)
$                5,454 $         6,901

Based on the above net exposures as at September 30, 2020, assuming that all other variables remain constant, a 5% appreciation or deterioration of the Canadian dollar against the U.S. dollar would result in a corresponding increase or decrease, respectively on the Company's net loss of approximately $210 (December 31, 2019 – $448).

The Company is also exposed to currency risk on the Euro; however, management estimates such risk relating to an appreciation or deterioration of the Canadian dollar against the Euro would have limited impact on the operations of the Company.

RELATED PARTY TRANSACTIONS

Directors and key management personnel control 24% of the voting shares of the Company as at September 30, 2020 (December 31, 2019 – 23%).

During the three and nine months ended September 30, 2020 the Company paid GVI, a company controlled by the Chief Executive Officer, a total of $21 and $64, respectively, (2019 – $21 and $64) for business administration services, $59 and $178, respectively, (2019 – $77 and $230) in rental costs and $9 and $28, respectively, (2019 – $12 and $36) for information technology support services. The business administration services summarized above are provided to the Company through a consulting agreement with GVI.

Clinical research services are provided through a consulting agreement with GVI Clinical Development Solutions Inc. ("GVI CDS"), a company controlled by the Chief Executive Officer. Pharmacovigilance and safety, regulatory support, quality control and clinical support are provided to the Company through the GVI CDS agreement. During the three and nine months ended September 30, 2020, the Company paid GVI CDS $27 and $120, respectively, (2019 – $79 and $331) for clinical research services.

| 29 |

| --- |

Management’sDiscussion and Analysis

Research and development services are provided through a consulting agreement with CanAm Bioresearch Inc. ("CanAm"), a company controlled by a close family member of the Chief Executive Officer. During the three and nine months ended September 30, 2020, the Company paid $6 and $6, respectively, (2019 – nil and $118) for research and development services.

These transactions have been measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties.

As at September 30, 2020, included in accounts payable and accrued liabilities is $18 (December 31, 2019 – $95) payable to GVI, $13 (December 31, 2019 – $56) payable to GVI CDS and $7 (December 31, 2019 – nil) payable to CanAm. These amounts are unsecured, payable on demand and non-interest bearing.

Effective July 18, 2016, the Company renewed its consulting agreement with its Chief Executive Officer, through A.D. Friesen Enterprises Ltd., a company owned by the Chief Executive Officer, for a term of five years, at a rate of $300 annually, increasing to $315 annually, effective January 1, 2017 and increasing to $331 annually, effective January 1, 2019. The Company may terminate this agreement at any time upon 120 days’ written notice. There were no amounts payable to A.D. Friesen Enterprises Ltd. as a result of this consulting agreement as at September 30, 2020 or December 31, 2019. Any amounts payable to A.D. Friesen Enterprises Ltd. are unsecured, payable on demand and non-interest bearing.

OFF-BALANCE SHEET ARRANGEMENTS

The Company does not have any off-balance sheet arrangements other than as discussed above.

OUTLOOK

The Company is primarily focusing on:

Maintaining and growing AGGRASTAT^®^ sales in the United States

The Company continues to work to expand the sales of AGGRASTAT^®^ in the United States. The use of AGGRASTAT^®^ is recommended by the AHA and ACC Guidelines for the treatment of ACS. AGGRASTAT^®^ has been shown, to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with NSTE ACS.

As stated previously, one of the Company’s primary ongoing research and development activities is the continued development and further implementation of a new regulatory, brand and life cycle management strategy for AGGRASTAT^®^.

An important aspect of the AGGRASTAT^®^ strategy was the revision of its approved prescribing information. On October 11, 2013, the Company announced that the FDA approved the AGGRASTAT^®^ HDB regimen, as requested under Medicure's supplemental new drug application (“sNDA”). The AGGRASTAT^®^ HDB regimen (25 mcg/kg within 5 minutes, followed by 0.15 mcg/kg/min) has become the recommended dosing for the reduction of thrombotic cardiovascular events in patients with NSTE ACS.

The Company believes that further expanded indications and dosing regimens could provide added value to further maximize the revenue potential for AGGRASTAT^®^. The Company is currently exploring the potential to make such changes, and the Company may need to conduct appropriate clinical trials, obtain positive results from those trials, or otherwise provide support in order to obtain regulatory approval for such proposed indications and dosing regimens.

On September 1, 2016, the Company announced that it had received approval from the FDA for its bolus vial product format for AGGRASTAT^®^. The product format is a concentrated, pre-mixed, 15 ml vial designed specifically for convenient delivery of the AGGRASTAT^®^ bolus dose (25 mcg/kg). Development of the bolus vial was in response to feedback from interventional cardiologists and catheterization lab nurses from across the United States. Commercial launch of the bolus vial took place in October of 2016 and the Company continues to believe this product format will have a positive impact on hospital utilization of AGGRASTAT^®^.

The Company is also providing funding for a number of investigator sponsored research projects targeting contemporary utilization of AGGRASTAT^®^ relative to its competitors. On June 29, 2020, the Company announced that results from the investigator sponsored FABOLUS-FASTER Phase 4 clinical trial, using AGGRASTAT^®^, have been published in Circulation, a peer-reviewed journal of the American Heart Association.

| 30 |

| --- |

Management’sDiscussion and Analysis

Growing sales of ZYPITAMAG^TM^in the United States

On September 30, 2019 the Company announced that through its subsidiary, Medicure International Inc., it has acquired the ownership of ZYPITAMAG^TM^ from Zydus for U.S. and Canadian markets. Under terms of the agreement, Zydus will receive an upfront payment of US$5,000 and US$2,000 in deferred payments to be made over the next four years, as well as contingent payments on achievement of milestones and royalties related to net sales.

Previously, on December 14, 2017, the Company acquired from Zydus, an exclusive license to sell and market ZYPITAMAG^TM^, a branded cardiovascular drug, in the United States and its territories for a term of seven years with extensions to the term available. ZYPITAMAG^TM^ is used for the treatment of patients with primary hyperlipidemia or mixed dyslipidemia and was approved in July 2017 by the FDA for sale and marketing in the United States. On May 1, 2018 ZYPITAMAG^TM^ became commercially available in retail pharmacies throughout the United States. The Company’s product launch utilized its existing commercial infrastructure and while not an in-hospital product like AGGRASTAT^®^, ZYPITAMAG^TM^ added to the Company’s cardiovascular portfolio and expanded the Company’s reach to new patients. ZYPITAMAG^TM^ contributed revenue of $105 and $371, respectively, to the Company for the three and nine months ended September, 2020 compared to $78 and $87 during the three and nine months ended September 30, 2019. The Company continues to work towards growing the ZYPITAMAG^TM^ brand, usage of the product and revenues from ZYPITAMAG^TM^.

On June 25, 2020, the Company announced the launch of a direct to patient online pharmacy program for the distribution of ZYPITAMAG^TM^in the United States.

This program offers many advantages to Medicure to facilitate an increase in patient access to ZYPITAMAG^TM^ for patients who hold a prescription, which includes direct shipment of the product to a patient’s home at no cost, the processing of prior authorizations, and direct to patient refill reminders. Ultimately, marketing and distribution of ZYPITAMAG^TM^through this program will provide reduced costs to the patient, including no retail pharmacy filling fees, and increase the availability of the product to consumers. It also provides a seamless process for physicians and prescribers, and reduces their workload by processing any prior authorization.

Acquisitions, licensing or marketingpartnerships for new commercial products

The Company continues to explore additional opportunities for the acquisition or licensing of other cardiovascular products that fit the commercial organization.

Developing additional cardiovasculargeneric and reformulation products

On August 13, 2018, the Company announced that the FDA has approved its ANDA for SNP. SNP is indicated for the immediate reduction of blood pressure for adult and pediatric patients in hypertensive crisis. The product is also indicated for producing controlled hypotension in order to reduce bleeding during surgery and for the treatment of acute congestive heart failure) The filing of the ANDA had been previously announced by the Company on December 13, 2016. Medicure’s SNP has recently become available in the United States with sales of $6 and $54, respectively, being recorded for the three and nine months ended September 30, 2020 from SNP.

Medicure is also developing two additional generic versions of acute cardiovascular drugs and is exploring other potential opportunities.

On August 20, 2020, the Company announced that it entered into a License, Manufacture and Supply Agreement with RLS for a cardiovascular biosimilar product.

CONTROLS

The Company is not required to certify on the design and evaluation of the Company's Disclosure Controls and Procedures (“DC&P”) and Internal Controls over Financial Reporting (“ICFR”) under Canadian securities requirements. However, the Company is required to certify for the Securities Exchange Commission. Information can be found in the Company's Annual Report on Form 20-F for the year ended December 31, 2019.

RISKS AND UNCERTAINTIES

Risks and uncertainties relating to the Company and its business can be found in the “Risk Factors” section of its Annual Report on Form 20-F for the year ended December 31, 2019, which can be obtained on SEDAR (www.sedar.com) and are not discussed extensively here.

| 31 |

| --- |

Management’sDiscussion and Analysis

Disease outbreaks may negatively impact the performance of the Company. A local, regional, national or international outbreak of a contagious disease, including the COVID 19 coronavirus, Middle East Respiratory Syndrome, Severe Acute Respiratory Syndrome, H1N1 influenza virus, avian flu or any other similar illness, could interrupt supplies and other services from third parties upon which the Company relies (including contract manufacturers, marketing and transportation and logistics providers), decrease demand for our products, decrease the general willingness of the general population to travel, cause staff shortages, reduced customer demand, and increased government regulation, all of which may materially and negatively impact the business, financial condition and results of operations of the Company. In particular, if the current outbreak of the COVID 19 coronavirus continues or increases in severity, the Company could experience difficulty in executing it strategic plans and the marketing, sales, production, logistics and distribution of its products could be severely disrupted. These events could materially and adversely affect the Company’s business and could have a material adverse effect on the Company’s liquidity and its financial results.

While the Company’s approved product portfolio has grown to AGGRASTAT^®^, ZYPITAMAG^TM^, PREXXARTAN^®^, which is currently on hold, and SNP, with a marketing agreement entered into in January of 2019, the Company still has products that are currently in the research and development stages. The Company may never develop another commercially viable drug product approved for marketing. To obtain regulatory approvals for its products and to achieve commercial success, human clinical trials must demonstrate that the new chemical entities are safe for human use and that they show efficacy, and generic drug products under development need to show analytical equivalence and /or bioequivalence to the referenced product on the market. Unsatisfactory results obtained from a particular study or clinical trial relating to one or more of the Company’s products may cause the Company to reduce or abandon its commitment to that program.

If the Company fails to successfully complete its development projects, it will not obtain approval from the FDA and other international regulatory agencies, to market its these products. Regulatory approvals also may be subject to conditions that could limit the market its products can be sold in or make either products more difficult or expensive to sell than anticipated. Also, regulatory approvals may be revoked at any time for various reasons, including for failure to comply with regulatory requirements or poor performance of its products in terms of safety and effectiveness.

The Company’s business, financial condition and results of operations are likely to be adversely affected if it fails to maintain or obtain regulatory approvals in the United States, Canada and abroad to market and sell its current or future drug products, including any limitations imposed on the marketing of such products.

In the near-term, a key driver of revenues will be the Company's ability to maintain or grow hospital sales of AGGRASTAT^®^, the ability to grow sales of ZYPITAMAG^TM^ and SNP and the development and/or acquisition of new products.

The Company’s future operations are dependent upon its ability to grow sales of AGGRASTAT^®^, successfully grow sales of ZYPITAMAG^TM^and SNP, to develop and/or acquire new products, and/or secure additional capital, which may not be available under favorable terms or at all.

ADDITIONAL INFORMATION

Additional information regarding the Company, including the Company’s Annual Report on Form 20-F for the year ended December 31, 2019, can be obtained on SEDAR (www.sedar.com). A copy of this MD&A will be provided to anyone who requests it.

32

Exhibit 99.3

FORM 52-109FV2CERTIFICATION OF INTERIM FILINGSVENTURE ISSUER BASIC CERTIFICATE

I, Albert D. Friesen, Chief Executive Officer of Medicure Inc., certify the following:

1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”)<br>of Medicure Inc. (the “issuer”) for the interim period ended September 30, 2020.
2. No misrepresentations: Based on my knowledge, having exercised reasonable diligence, the interim filings do not<br>contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to<br>make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the<br>interim filings.
--- ---
3. Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial report<br>together with the other financial information included in the interim filings fairly present in all material respects the financial<br>condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.
--- ---

Date: November 11, 2020

/s/ Albert D. Friesen_______________________

Albert D. Friesen

Chief Executive Officer

NOTE TO READER<br><br> <br><br> In contrast to the certificate required for non-venture issuers under National Instrument 52-109 Certification of Disclosure in Issuers’ Annual and Interim Filings (NI 52-109), this Venture Issuer Basic Certificate does not include representations<br> relating to the establishment and maintenance of disclosure controls and procedures (DC&P) and internal control over financial<br> reporting (ICFR), as defined in NI 52-109. In particular, the certifying officers filing this certificate are not making any representations<br> relating to the establishment and maintenance of<br><br> <br><br><br> <br>i.      controls<br> and other procedures designed to provide reasonable assurance that information required to be disclosed by the issuer in its annual<br> filings, interim filings or other reports filed or submitted under securities legislation is recorded, processed, summarized and<br> reported within the time periods specified in securities legislation; and<br><br> <br><br><br> <br>ii.    a<br> process to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements<br> for external purposes in accordance with the issuer’s GAAP.<br><br> <br><br><br> <br>The issuer’s certifying officers are responsible for ensuring<br> that processes are in place to provide them with sufficient knowledge to support the representations they are making in this certificate.<br> Investors should be aware that inherent limitations on the ability of certifying officers of a venture issuer to design and implement<br> on a cost effective basis DC&P and ICFR as defined in NI 52-109 may result in additional risks to the quality, reliability,<br> transparency and timeliness of interim and annual filings and other reports provided under securities legislation.

Exhibit 99.4

FORM 52-109FV2CERTIFICATION OF INTERIM FILINGSVENTURE ISSUER BASIC CERTIFICATE

I, James Kinley, Chief Financial Officer of Medicure Inc., certify the following:

1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”)<br>of Medicure Inc. (the “issuer”) for the interim period ended September 30, 2020.
2. No misrepresentations: Based on my knowledge, having exercised reasonable diligence, the interim filings do not<br>contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to<br>make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the<br>interim filings.
--- ---
3. Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial report<br>together with the other financial information included in the interim filings fairly present in all material respects the financial<br>condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.
--- ---

Date: November 11, 2020

/s/ James Kinley_______________________

James Kinley

Chief Financial Officer

NOTE TO READER<br><br> <br><br> In contrast to the certificate required for non-venture issuers under National Instrument 52-109 Certification of Disclosure in Issuers’ Annual and Interim Filings (NI 52-109), this Venture Issuer Basic Certificate does not include representations<br> relating to the establishment and maintenance of disclosure controls and procedures (DC&P) and internal control over financial<br> reporting (ICFR), as defined in NI 52-109. In particular, the certifying officers filing this certificate are not making any representations<br> relating to the establishment and maintenance of<br><br> <br><br><br> <br>i.      controls<br>and other procedures designed to provide reasonable assurance that information required to be disclosed by the issuer in its annual<br>filings, interim filings or other reports filed or submitted under securities legislation is recorded, processed, summarized and<br>reported within the time periods specified in securities legislation; and<br><br> <br>ii.    a<br>process to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements<br>for external purposes in accordance with the issuer’s GAAP.<br><br> <br>The issuer’s certifying officers are responsible for ensuring<br> that processes are in place to provide them with sufficient knowledge to support the representations they are making in this certificate.<br> Investors should be aware that inherent limitations on the ability of certifying officers of a venture issuer to design and implement<br> on a cost effective basis DC&P and ICFR as defined in NI 52-109 may result in additional risks to the quality, reliability,<br> transparency and timeliness of interim and annual filings and other reports provided under securities legislation.

Report a Problem

Category
Description
Email (optional, for follow-up)